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ABC:   ATP binding cassette 
ABCP:   Placenta specific ABC transporter 
Abl:   Abelson tyrosine kinase 
ADME-Tox: Absorption, distribution, metabolism, excretion and toxicity 
ADP:  Adenosine diphosphate 
AhR:  Aryl hydrocarbon receptor 
ALL:  Acute lymphoid leukemia 
AML:  Acute myeloid leukemia 
ATP:  Adenosine triphosphate 
Bcr:   Breakpoint cluster region protein 
BCRP:   Breast cancer resistance protein 
BSA:   Bovine serum albumin 
CAR:  Constitutive androstane receptor 
CFTR:  Cystic fibrosis transmembrane conductance regulator 
CHO:   Chinese hamster ovary (cells) 
CML:   Chronic myeloid leukemia 
CSC:  Cancer stem cell 
DB:    Disaggregating buffer 
DNA:   Deoxyribonucleic acid 
DOC:   Deoxycholate 
DPBS:   Dulbecco’s modified phosphate buffered saline 
ECL:   Enhanced chemiluminescence 
EDTA:   Ethylene diamine tetraacetic acid 
EGF:   Epidermal growth factor 
ER:   Endoplasmic reticulum  
hEGF:   Human (recombinant) epidermal growth factor 
huES:  Human embryonic stem cell 
EGFR:   Epidermal growth factor receptor 
FISH:   Fluorescent in situ hybridization 
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FTC:   Fumitremorgin C 
GFP:   Green fluorescent protein 
HPLC-MS:  High pressure liquid chromatography - mass spectrometry 
MDR:   Multidrug resistance 
MRP:  Multidrug resistance associated protein 
mTOR:   Mammalian target of rapamycin 
MX:   Mitoxantrone 
MXR:   Mitoxantrone resistance protein 
NBD:  Nucleotide binding domain 
NSCLC:  Non-small cell lung cancer 
PDK1:   Phosphoinositide-dependent protein kinase-1 
PE:    Phycoerythrin 
PFA:   Paraformaldehyde 
Pgp:   P-glycoprotein 
PhIP:  2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine 
Pi:   Inorganic phosphate 
PI3K:   Phosphatidylinositol 3-kinase 
PIP3:   Phosphatidylinositol (3,4,5) trisphosphate 
PVDF:   Polyvinylidene difluoride (membrane) 
PXR:  Pregnane X receptor 
RTK:  Receptor tyrosine kinase 
SD:   Standard deviation 
SDS:   Sodium dodecyl sulfate 
SE:    Standard error 
Sf9:   Spodoptera frugiperda (ovarian cells) 
SP:   Side population 
SUR1:  Sulfonylurea receptor 
TCA:   Trichloro acetic acid 
TEMED:   N,N,N′,N′- tetramethyl ethylene diamine 
TMD:  Transmembrane domain 
WGA:   Wheat germ agglutinin 
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2. INTRODUCTION 
2.1. Multidrug resistance (MDR) and the discovery of P-glycoprotein 
(Pgp/MDR1/ABCB1) 
The appearance of drug resistance during the course of chemotherapy is a major 
impediment to successful cancer treatment that clinicians have long been facing (1). 
Extensive research on model cells in vitro cultured in increasing doses of anti-cancer 
drugs has revealed various cellular mechanisms of drug resistance. Cultured cells 
maintained under drug selection pressure might become resistant to a single agent or a 
small number of functionally related drugs by loss of a cell surface receptor or transporter 
for the drug, by alteration of the intracellular target of the drug or by increase of cellular 
repair mechanisms correcting the drug-induced fatal molecular damage (2,3). In vitro 
cellular exposure to a single anti-cancer drug might also lead to the emergence of 
multidrug resistance (MDR), when cells acquire resistance not only to the selecting 
agent but also develop cross resistance towards a wide variety of chemically and target-
wise unrelated drugs (2,3). Studies on the mechanisms of MDR were initiated with the 
1973 discovery of the active outward transport of the chemotherapeutic drug daunomycin 
from resistant tumor cells, described by Keld Dano (4). In 1974, a seminal study of Ling 
and Thompson characterized Chinese hamster ovary (CHO) cells which were subjected to 
stepwise selection with increasing doses of colchicine (5). Colchicine-resistant CHO cells 
showed cross resistance to several apparently unrelated compounds, and the degree of 
cross resistance positively correlated with that of colchicine resistance (5,6). Analysis of 
the isolated colchicine-resistant CHO cells revealed that reduced cellular drug uptake 
rather than altered intracellular colchicine binding was responsible for colchicine 
resistance (5), and it was further suggested that energy-dependent alterations in the 
permeability of the plasma membrane could account for the pleiotropic phenotype of the 
drug resistant cells (6,7). In 1976, a 170 kDa glycoprotein in the cell surface of resistant 
CHO cells was identified as the major molecular determinant of decreased drug 
permeability, which was hence designated as P-glycoprotein (Pgp) (MDR1, ABCB1) (8). 
The finding that the relative amount of Pgp in the cell membrane showed strong positive 
correlation with the degree of drug resistance also provided evidence that the presence of 
Pgp was functionally related to the drug resistant phenotype (8). In subsequent reports, 
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expression of Pgp was demonstrated in hamster, mouse and human tumor cell lines 
displaying simultaneous resistance to various drugs and in human tumor samples as well 
(9-14), suggesting a general molecular basis for the emergence of multidrug resistance 
and its potential relevance in cancer therapy. Pgp was cloned in 1986, and its predicted 
amino acid sequence was found to contain the consensus sequence for two potential ATP 
binding cassettes (ABC). The evolutionarily conserved ATP binding domain had already 
been known to couple the energy of ATP hydrolysis to various cellular functions in 
bacteria, including membrane transport processes (15). Based on the strong homology 
observed between Pgp and bacterial transporters, Pgp was proposed to function as an 
efflux pump responsible for the removal of various drugs by an ATP-dependent 
mechanism thereby causing multidrug resistance (16-22). 
 
2.2. Atypical multidrug resistance and the discovery of 
BCRP/MXR/ABCP/ABCG2 
Although the concept that the function of a single protein accounted for the MDR 
phenomenon initially seemed to hold out promising implications for cancer treatment, it 
soon became obvious that cellular factors other than Pgp also operated in multidrug 
resistant cells. The notion that vincristine-selected HL60 and doxorubicin-selected 
H69AR cells displayed a multidrug resistant phenotype but were devoid of Pgp 
expression led to the cloning of a novel ABC transporter termed as multidrug resistance 
associated protein (MRP) (MRP1, ABCC1) (23,24). An early study describing detailed 
pharmacological characterization of MRP revealed that forced expression of the protein 
also conferred a multidrug resistant phenotype which was similar but not identical to that 
caused by Pgp (25).  
In search for alternate cellular factors involved in MDR, studies using the in vitro drug 
selection approach continued. In the 1990s, MCF-7 human breast carcinoma cells 
exposed to stepwise selection with doxorubicin (Adriamycin) in the presence of the Pgp 
inhibitor verapamil (MCF-7/AdrVp) were demonstrated to lack overexpressed Pgp and 
MRP and to show a unique (‘atypical’) cross-resistance pattern. MCF-7/AdrVp cells also 
displayed enhanced ATP-dependent efflux of daunomycin and rhodamine 123 implying 
the presence of an as yet unknown energy-dependent transport protein (26,27). 
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Investigations using these MCF-7/AdrVp cells, other mitoxantrone-selected cell lines 
showing an atypical drug resistance pattern; and analysis of a human cDNA library led to 
the discovery of the third ABC protein associated with the transport of various 
chemotherapeutics and multidrug resistance, that was named after the biological systems 
from which it was simultaneously but independently identified as breast cancer 
resistance protein (BCRP), mitoxantrone resistance protein (MXR) or placenta specific 
ABC transporter (ABCP) (28-30).  
 
2.3. The ABCG2 protein: structure, function, tissue distribution and putative 
physiological role 
BCRP/MXR/ABCP belongs to the superfamily of ATP binding cassette (ABC) 
transporter proteins which represents one of the largest and most diverse groups of 
transmembrane proteins. Members of the ABC protein superfamily share a structurally 
and functionally highly conserved protein module, the ATP binding cassette (ABC) (also 
known as nucleotide binding domain, NBD) , which is responsible for the binding and 
hydrolysis of ATP and thereby can energize inward (cellular or luminal accumulation, 
import) or outward (extrusion, export) transmembrane transport processes (15,31). ABC 
transporters are present in all species from microorganisms to man and are engaged in a 
variety of biological functions (31). 
The human genome encodes 48 ABC transporters which, based on gene structure, 
amino acid sequence alignments and domain organization, can be grouped into seven 
subfamilies from A to G. Protein members of the subfamilies are further denoted by 
Arabic numerals, therefore BCRP/MXR/ABCP which is the second member of the 
ABCG subfamily was designated as ABCG2 according to the standard nomenclature 
(32). The vast majority of human ABC proteins function as active transporters moving 
their substrates against a concentration gradient, but proteins functioning as channels (the 
cystic fibrosis transmembrane conductance regulator CFTR/ABCC7 which functions as a 
chloride ion channel) or receptors (the sulfonylurea receptors SUR1/ABCC8 and 
SUR2/ABCC9 which regulate an ATP-dependent potassium channel) are also present in 
the superfamily (32,33). Mutations in 18 of the human ABC genes have been linked to 
human diseases or phenotypes (34).  
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The human ABCG2 gene, which was mapped to be located on chromosome 4q22, 
spans over 66 kb and consists of 16 exons (30,35). Its gene product is a 655 amino acid 
72 kDa protein, which, similarly to all members of the ABC superfamily is built from 
two structurally and functionally characteristic units: the nucleotide binding domain and 
the transmembrane domain (Fig. 1). The nucleotide binding domain (NBD) which is 
responsible for releasing the energy of ATP hydrolysis carries three evolutionarily 
conserved sequence motifs, the Walker A (GXXGXGKS/T), the Walker B (hhhhD) and 
the ABC signature motif (LSGGQQ/R/KQR) (28-30,36). While the Walker A and 
Walker B motifs can be found in other nucleotide binding proteins as well (37), the ABC 
signature motif is a hallmark of the ABC transporter superfamily (36). The 
transmembrane domain (TMD) of ABCG2 is predicted to consist of six membrane 
spanning helices (38-40), and is most probably responsible for the recognition and 
handling of substrates. The hydrophilic amino terminal of ABCG2 contains the NBD, 
while the TMD is located in the relatively hydrophobic carboxyl terminal of the protein. 
This molecular configuration corresponds to one half of the Pgp polypeptide in a reverse 
domain arrangement (Fig. 1).  
 
Figure 1. Predicted membrane topology of ABCG2. ABCG2 is built from a nucleotide 
binding domain (NBD) and a transmembrane domain (TMD) of six membrane spanning helices. 
NBD consensus motifs are Walker A, Walker B and the signature. C592, C608 and C603 are 
involved in intra- and intermolecular disulfide bridge formation; amino acid at position 482 
affects substrate specificity (see text for details). Domain organization of ABCG2 compared with 
ABCB1 is shown. PM: plasma membrane; aa: amino acid. 
ABCG2 and targeted anti-cancer drugs                                                 Csilla Hegedüs, PhD thesis 
 12
It is widely accepted that a fully functional ABC transporter requires the presence of at 
least two NBDs and two TMDs, therefore the ABCG2 protein is recognized as a half-
transporter and is currently considered to work as a homodimer or homo-oligomer (28-
31,41-44). 
Similarly to all ABC proteins, the transport process performed by ABCG2 is energized 
by the hydrolysis of ATP. The two L-shaped NBDs dimerize in a head-to-tail orientation 
to form two composite catalytic sites; each involving the Walker A sequence of one and 
the ABC signature motif of the other NBD and sandwiching the nucleotides at the NBD 
dimer interface (45,46). The functional interaction and the formation of the substrate 
translocation pathway by two TMDs are also required for proper transporter function (47-
49). The ATP hydrolytic (catalytic) cycle has been profoundly investigated using the first 
discovered human MDR-ABC transporter molecule, Pgp. According to the alternating 
catalytic sites hypothesis first proposed by Senior et al in 1995, ATP binding at one 
catalytic site promotes the hydrolysis of ATP at the other catalytic site and ATP 
hydrolysis induces a conformation which prohibits ATP hydrolysis at the other site. 
Relaxation of this intermediate bearing high chemical potential results in the 
translocation of the bound substrate (50). A revised and extended model of the catalytic 
cycle of Pgp was presented by Sauna et al, suggesting that two hydrolysis events are 
required in each transport cycle (51). This model proposes that the first step of the 
catalytic cycle is the binding of the drug on the ‘ON’ drug-binding site, and the binding 
of ATP molecule(s) at one or both of the catalytic sites. There is no energetic requirement 
for this step. Hydrolysis of the first ATP molecule generates a conformational change that 
reduces the affinity of both the drug (possibly moving to the ‘OFF’ drug-binding site) and 
the nucleotide for Pgp. With the release of inorganic phosphate (Pi), the drug is extruded 
from Pgp. The subsequent release of ADP generates a conformation displaying high 
affinity for nucleotides but low affinity for drug and hydrolysis of the second ATP is 
initiated. The second ATP hydrolysis event is required for re-setting the transporter to 
regain its high affinity drug binding state and to enter a new cycle (51). The basic 
principles established by these models still guide further refinements. 
The classical pump model suggests that MDR-ABC transporters would remove their 
substrates from the cytoplasm, which apparently seem to conflict with the promiscuous 
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drug recognition and the high abundance of lipophilic substrates for both Pgp and 
ABCG2. Two alternative models therefore suggested that drug recognition by MDR-
ABC transporters occur in the lipid phase, and the protein translocates the drug directly 
from the membrane (hydrophobic vacuum cleaner) or extracts its substrate from the inner 
to the outer membrane leaflet similarly to lipid floppases (Fig. 2). A kinetic model 
describing the hydrophobic vacuum cleaner mechanism fit best with the experimental 
data obtained by microscopic analysis of the GFP-ABCG2-mediated cellular extrusion of 
mitoxantrone, indicating that ABCG2 removes mitoxantrone directly from the cell 
membrane (52). 
 
Figure 2. Transport models of MDR-ABC proteins. Instead of removing substrates from the 
cytoplasm as classical pumps, MDR-ABC proteins were suggested to interact with their 
substrates in the lipid phase. According to the hydrophobic vacuum cleaner model, MDR-ABC 
transporters extract their substrates directly from the plasma membrane. Alternatively, they 
might work similarly to lipid floppases. ABCG2 was shown to expel mitoxantrone directly from 
the plasma membrane (52). The energy of ATP hydrolysis is used for transport in all cases, 
which, for clarity is only shown in the hydrophobic vacuum cleaner model. PM: plasma 
membrane. 
 
The exact molecular mechanism of coupling the energy of ATP hydrolysis with the 
transport of substrates and the molecular basis of polyspecific drug binding of MDR-
ABC transporters are still unclear. Crystal structures of cytoplasmic NBDs or full 
polypeptides of several bacterial ABC transporters have been solved, including the entire 
Sav1866 multidrug exporter of Staphylococcus aureus, which is the bacterial homolog of 
human Pgp (53,54). The molecular snapshot of Sav1866 caught an outward facing 
conformation in an ADP-bound state, with the two NBDs in close proximity sandwiching 
the bound nucleotides. The structure indicates that residues from all transmembrane 
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helices are involved in forming a large cavity at the interface of the two TMDs, which 
serves as the translocation pathway for drugs. Rather than aligned side-by-side, the 
subunits are twisted so that and each NBD contacts both TMDs. To date, high resolution 
structural information regarding mammalian ABC transporters is only available for 
murine Pgp which shows 87% sequence identity with human Pgp (55). Structures of the 
apo and drug-bound murine Pgp revealed an inward facing conformation with a large 
intramembrane cavity bearing distinct drug-binding sites and two portals open to the 
inner leaflet and the cytoplasm that allow entry of hydrophobic drugs. Nevertheless, as 
each of the solved murine Pgp structures is in the absence of bound nucleotides and the 
two NBDs seem to locate unreasonably far apart, it can be debated whether these crystal 
structures have any physiological relevance. 
Gene expression of human ABCG2 is regulated by the binding of numerous 
transcription factors (56) and also by the usage of three alternative promoters. The 
transcribed ABCG2 mRNA species with different 5’ UTRs (untranslated regions) (exon 
1a, b and c) have been reported to display a tissue specific and tumor type specific 
expression pattern (57-60). ABCG2 transcripts carrying distinct 3’ UTRs were also 
reported in human embryonic stem cells (huES cells) and drug selected tumor cells, and 
stability and translation of these 3’ UTR ABCG2 mRNA variants were suggested to 
undergo miRNA-mediated control (58,61,62). The translated ABCG2 polypeptide 
undergoes folding and N-glycosylation at N596 in the endoplasmic reticulum (ER) and 
transits via the Golgi to the plasma membrane (Fig. 1). Full glycosylation at N596 is not 
prerequisite either for plasma membrane localization or for proper function of the 
transporter (41,63-65). The third extracellular loop of ABCG2 is relatively large and 
exposes three cysteine residues (C592, C603 and C608) which are involved in the 
formation of intra- and intermolecular disulfide bridges in the ER (Fig. 1). The 
intramolecular disulfide bridge (between C592 and C608) influences the plasma 
membrane targeting and the substrate specificity of ABCG2 (66-69) and the extracellular 
epitope formation for the anti-ABCG2 5D3 antibody as well (70,71). The intermolecular 
disulfide bridge covalently links two ABCG2 molecules via their C603 residues, thus 
generating a homodimer (66,72). Interestingly, the presence of C603 and the resulting 
intermolecular disulfide bond between two ABCG2 molecules is not essential for the 
ABCG2 and targeted anti-cancer drugs                                                 Csilla Hegedüs, PhD thesis 
 15
expression and proper function of the transporter (43,66,67,72,73). The third extracellular 
loop of ABCG2 has also been suggested to play role in the transmembrane transport and 
extracellular transfer of porphyrines (74). Regulation of the localization or function of 
ABCG2 by phosphorylation is currently controversial, as functional ABCG2 was shown 
to be unphosphorylated in epithelial and ovarian carcinoma cell lines (64); however, in 
prostate cancer cells phosphorylation of the transporter at T362 by Pim-1 kinase was 
reported (75). Involvement of signaling cascades in the expressional and functional 
regulation of ABCG2 is poorly understood. The ERK/MAPK cascade (60,76,77), the 
PI3K/Akt cascade (78-84), the p53/NFkappa-B pathway (85) and Hedgehog (Hh) 
signaling (86,87) have been proposed to regulate ABCG2. Correctly processed functional 
ABCG2 is degraded via the lysosome, while ABCG2 that is misfolded, 
underglycosylated or lacks the intramolecular disulfide bond is targeted to the ubiquitin-
mediated proteasomal proteolysis pathway (65).  
ABCG2 is predominantly expressed in the plasma membrane (88-90), however 
presence of the transporter has also been reported in lysosomal and mitochondrial 
membranes (91-93). While surface ABCG2 is believed to be part of the first line cellular 
defense machinery eliminating xenobiotics at the cell membrane, ABCG2 located in 
lysosomal compartments has been suggested to be involved in vesicular sequestration of 
intracellularly accumulated drugs (91), whereas mitochondrial ABCG2 has been reported 
to transport mitoxantrone (92) and to decrease 5-aminolevulinic acid (ALA)-mediated 
mitochondrial accumulation of protoporphyrin IX (93). Nevertheless, the presence, 
functional activity and biological relevance of ABCG2 located in subcellular 
compartments await confirmation from further studies. 
Northern blot, RT-PCR and immunohistochemistry revealed that human ABCG2 is 
highly expressed in placental syncytiotrophoblasts, in the epithelium of the small and 
large intestine and the colon, in biliary canaliculi, in the proximal tubule of the kidney, in 
the zona reticularis of the adrenal gland, in Sertoli/Leydig cells of the testis, in alveolar 
pneumocytes of the lung, in breast tissue, in veinous and capillary endothelium and in the 
endothelium of the central nervous system (28,94,95). The physiological tissue 
distribution of ABCG2 strongly indicates a general xenoprotective function for the 
transporter. ABCG2 is also expressed in the side population (SP) of stem cells of various 
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origins and is currently believed to maintain the undifferentiated state of stem cells and/or 
to contribute to their protection against endo- and exotoxins, various stress conditions and 
hypoxia (70,96-98). ABCG2 is also present in the cell membrane of erythrocytes, and 
defines the blood group system Junior (Jr) (99,100). 
ABCG2 knockout (Bcrp1-/-) mice proved to be viable and fertile (101). Nevertheless, 
when Bcrp1 null mice were challenged with the dietary phototoxin pheophorbide a (a 
breakdown product of chlorophyll) they developed protoporphyria and (in some cases 
lethal) phototoxic lesions on light-exposed skin on the ear (102). Pheophorbide a was 
shown to be a transported substrate of ABCG2 (102,103). Bcrp null mice were also 
reported to display increased systemic exposure to the dietary carcinogen PhIP (104). 
Moreover Bcrp1-/- mice showed increased sensitivity to mitoxantrone (101). These data 
further suggest a key role of ABCG2 in protecting the body from endogenous and 
environmental toxins. 
Recently, orchestrated co-operation of uptake transporters, drug metabolizing enzymes 
and efflux transporters, including MDR-ABC proteins, in cellular and systemic protection 
of the body has been suggested. As several features of this molecular machinery resemble 
those of the classical immune system (46,105), it has been designated as a 
chemoimmunity defense system (46) (Table 1).  
 
 Immune system Chemoimmune system 
Target Water-soluble antigens Hydrophobic toxins 
Physiological functions Recognition, elimination Recognition, elimination 
Major types Innate, adaptive Innate, adaptive 






Table 1. Comparison of the classical immune system and the chemoimmune system. 
 
Wet laboratory studies reporting upregulation of ABCG2 by xenobiotic sensing 
receptors (which also regulate expression of various uptake transporters, drug 
metabolizing enzymes and other MDR-ABC transporters) such as the aryl hydrocarbon 
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receptor (AhR) (106-109), the constitutive androstane receptor (CAR) (110,111) or the 
pregnane X receptor (PXR) (110) also support the concept that ABCG2 might be 
involved in a complex molecular chemoimmunity network. 
 
2.4. ABCG2 in cancer 
Following identification and cloning of ABCG2, its overexpression was soon 
demonstrated to be associated with the multidrug resistant phenotype of cancer cell lines 
of various origins, such as breast, colon, gastric and ovarian carcinoma, fibrosarcoma and 
myeloma (29,112,113). Nevertheless, whether or not functional ABCG2 is present and 
can be associated with drug resistance in human tumors has raised controversies. Samples 
from patients with hematological malignancies such as acute myeloid leukemia (AML) 
or acute lymphoid leukemia (ALL) were both reported to express relatively high and low 
or undetectable levels of ABCG2, questioning the prognostic significance of the 
transporter (90,114-121); while primitive chronic myeloid leukemia (CML) cells were 
shown to express functional ABCG2 (122,123). Similarly, immunohistochemical staining 
of ABCG2 in a panel of human solid tumor samples revealed ABCG2 expression in only 
a single case of small-intestinal adenocarcinoma (out of 57 cryosections of various tumor 
origins) in one study (90), whereas frequent expression of the transporter was described 
in a panel of 150 samples of 21 tumor origins in another paper (124). A case report also 
associated ABCG2 overexpression with acquired drug resistance in a non-small cell lung 
cancer (NSCLC) patient (125). Most probably due to the lack of validated standard 
methods to detect MDR-ABC transporter expression and function in human tumor 
tissues, ABCG2 (together with Pgp and MRP1) is still being attributed a controversial 
role in clinical oncology. Importantly, as ABCG2 shows relatively high physiological 
expression at pharmacological tissue barriers (in the gut, the liver, the kidney, the blood-
brain barrier, the blood-testis barrier or feto-maternal barrier) recent studies have also 
proposed its major influence on drug absorption, distribution, metabolism, excretion 
and toxicity (ADME-Tox) (126,127). 
ABCG2 is the molecular determinant of the side population (SP) of normal stem cells 
under physiological conditions (70). The SP fraction has also been isolated from various 
hematological and solid tumors (81,128-130); and cancer SP cells were shown to 
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recapitulate several properties of normal stem cells such as self-renewal or resistance to 
chemotherapeutics (81,129,131,132). The cancer stem cell (CSC) hypothesis suggests 
that drug resistant cancer stem cells are driving tumor re-growth and ABCG2 is probably 
a pivotal efflux transporter that contributes to preserving the CSC sanctuary under 
chemotherapeutic pressure (128,132). Notably, a small subpopulation of AML and CML 
cells were reported to show remarkably high expression of ABCG2. These cells were also 
CD34+CD38- that is a surface antigen marker combination which is currently believed to 
define the cancer stem cell population in these leukemias (119,122,123). 
 
2.5. Substrates and inhibitors of the ABCG2 protein 
The hypothesis that ABCG2 has an essential physiological role (which would assume 
that it transports an important physiological substrate) can be challenged by the notions 
that Bcrp1-/- mice, at least in controlled sterile animal facilities, are viable and fertile; 
and human individuals of the Jr(a-) blood type who lack cell surface ABCG2 appear 
phenotypically normal (99-101). These observations could also be explained by MDR-
ABC transporters having an overlapping physiological substrate spectrum and thus 
fulfilling a replaceable physiological function. Indeed, physiological substrates for 
ABCG2 have long remained elusive. Two genome-wide association studies identified a 
single nucleotide polymorphism (SNP) in the ABCG2 gene as a major modulator of 
serum uric acid levels and as a potential risk factor for hyperuricemia and gout (133,134). 
In a follow-up report ABCG2 was shown to transport uric acid (135). 
ABCG2 transports a remarkably wide spectrum of chemically and target-wise 
unrelated drugs (56,126,136,137). Selected drug substrates of ABCG2 are listed in Table 
2. Accordingly, ABCG2 has been shown to confer cellular resistance against various 
clinically relevant anti-cancer drugs; however, correlation between results obtained in 
primary tumors and tumor cell lines has not always been straightforward. Importantly, 
ABCG2 substrates acting as competitive inhibitors might play an attractive role in 
chemo-sensitization of drug resistant cells during combination therapies. Interestingly, 
numerous drug-selected cancer cell lines were shown to overexpress mutant ABCG2 
protein variants, namely ABCG2 R482G or ABCG2 R482T (28,29,138-140). Amino acid 
substitutions at the 482 position were shown to affect the substrate specificity of the 
ABCG2 and targeted anti-cancer drugs                                                 Csilla Hegedüs, PhD thesis 
 19
transporter (141,142). Interestingly, even though the R482G and R482T gain-of-function 
mutations frequently appeared in drug-selected cell lines, only the wild-type ABCG2 






Campthotecins Topotecan, irinotecan, SN-38 
Kinase inhibitors 
Flavopiridol, quercetin, imatinib, danusertib, 
gefitinib, erlotinib, lapatinib, sorafenib, 
sunitinib 
Antihypertensives Prazosin 
Antivirals Zidovudine (AZT), lamivudine 
Antibiotics Ciprofloxacin, ofloxacin, norfloxacin 
 
Table 2. Selected drug substrates of the wild-type ABCG2 multidrug transporter. The list 
was compiled from (46,56,126,127,136). 
 
Fumitremorgin C (FTC), a mycotoxin extracted from Aspergillus fumigatus had been 
reported to reverse atypical drug resistance before ABCG2 itself was identified and 
cloned (144). Later, FTC was confirmed to selectively inhibit the function of ABCG2 
(145). FTC showed little toxicity in vitro, however was reported to cause tremors in 
cockerels, while two related compounds FTA and FTB also showed neurotoxic effects in 
mammals, precluding in vivo applicability of FTC (145). The FTC analogue compounds 
Ko132, Ko134 and Ko143 were reported to be potent, specific and low-toxicity inhibitors 
of ABCG2 in vitro, and also inhibited the function of the transporter in vivo in mice 
(146). Multispecific MDR-ABC transporter inhibitors showing both in vitro and in vivo 
activity are also available, such as elacridar (GF120918) and tariquidar (XR-9576) which 
inhibit Pgp and ABCG2; or cyclosporine A (CSA) and biricodar (VX-710) which inhibit 
Pgp, MRP1 and ABCG2 (126). Most of these multispecific inhibitors have already had 
history as potential (Pgp-mediated) MDR reversal agents applied in clinical trials, which 
unfortunately all ended with disappointing results (126,136). Inefficiency and/or toxicity 
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of the MDR-ABC inhibitors observed are currently believed to have resulted from the 
recruitment of patient cohorts not biased for MDR-ABC transporter expression and from 
interference with the physiological xenoprotective function of the targeted transporters. 
Recently, several compounds have been identified to which drug resistant cancer cells 
overexpressing Pgp showed an unexpected hypersensitivity (collateral sensitivity) (147-
149). Whether drugs that selectively kill ABCG2-expressing cancer cells exist is yet to be 
elucidated (150). Nevertheless, novel promising therapeutic strategies seem to emerge 
that aim to selectively target and exploit MDR-ABC transporter overexpression of cancer 
cells (136). 
 
2.6. Targeted cancer therapy 
Conventional chemotherapeutics, which target DNA replication, DNA uncoiling, 
nucleic acid metabolism or microtubule function, cannot distinguish between rapidly 
dividing normal and cancer cells. The notion that proliferation and survival of cancer 
cells often depend on a single activated oncogene (a phenomenon currently believed to 
render cancer cells especially susceptible to interference with the function of the 
oncogene and the oncogene-associated signaling pathways, recently also termed as 
oncogene addiction) provided a rationale for the design and clinical application of 
molecularly-targeted cancer therapeutic strategies that would specifically eliminate the 
malignant cells (151-154). Oncogenes that can confer oncogene addiction most 
frequently code for kinases (152,155-157). The human kinome has been shown to 
contain 518 putative kinase genes which constitute about 1.7% of the human genes (158). 
Chromosomal mapping of the human kinase genes revealed that 164 kinases located to 
amplicons frequently appearing in tumors (158); furthermore, an unexpectedly large 
number of putative driver (playing a causal role in oncogenesis) and passenger somatic 
mutations in kinomes of various tumor origins has recently been described (159,160). 
Protein kinases which have been validated as major contributors to oncogenesis, and 
therefore have already served as promising drug targets include the Bcr-Abl and the 
Epidermal Growth Factor Receptor (EGFR) kinase enzymes. 
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2.6.1. Bcr-Abl signaling in cancer and its small molecule inhibitors 
Bcr-Abl is an oncogenic non-receptor tyrosine kinase whose activity is required for 
the pathogenesis of chronic myeloid leukemia (CML), a clonal myeloproliferative 
disorder of hematopoetic stem cell (HSC) origin. The genetic hallmark of CML is the 
Philadelphia chromosome (a shortened chromosome 22) generated by the 
t(9;22)(q34;q11) reciprocal translocation, which can be detected in approximately 95% of 
CML patients. This chromosomal translocation fuses the Abl proto-oncogene (the human 
homologue of v-Abl carried by the Abelson murine leukemia virus) physiologically 
located on chromosome 9 to the Bcr (breakpoint cluster region) gene on chromosome 22, 
generating the Bcr-Abl hybrid gene. Depending on the exact location of the breakpoints 
in Bcr (designated as major, minor and micro breakpoint cluster regions; M-bcr, m-bcr 
and µ-bcr respectively) and on alternative splicing of the different transcripts, four fusion 
protein variants can be generated, with molecular weights of 190 kDa, 210 kDa or 230 
kDa. Most CML patients carry the 210 kDa Bcr-Abl kinase (161,162). The fusion-
mediated loss of the N-terminal myristoylation site of Abl and the Bcr coiled-coil motif-
mediated interference with the kinase autoinhibitory domains (Src homology domains, 
SH2 and SH3) of Abl results in constitutive tyrosine kinase activity and leukemogenic 
potential of Bcr-Abl (163,164) (Fig. 3). The autophosphorylation of Bcr-Abl at Tyr177 
links Bcr-Abl to mitogenic Ras signaling through its direct interaction with the adaptor 
protein Grb2 (growth factor receptor-bound protein 2), a phenomenon which is required 
for the transforming potential of the fusion kinase (165-167) (Fig. 3). Bcr-Abl also 
transduces pro-survival and anti-apoptotic signals, and signals resulting in altered cell 
adhesion and migration (163,168). 
Since Bcr-Abl plays a pivotal role in leukemogenesis, it was soon recognized as a 
promising molecular drug target. The first identified small molecule inhibitor showing 
potent in vitro and in vivo Abl inhibitory activity was imatinib (Gleevec/Glivec/imatinib-
mesylate/CGP57148/STI-571) (169). Imatinib was soon reported to suppress 
proliferation and induce apoptosis of Bcr-Abl positive primary and model cells, setting 
the stage to its translation to clinical use (170-173). Imatinib displays an additional 
inhibitory activity on c-KIT (stem cell factor receptor, CD117) and PDGFR (platelet-
derived growth factor receptor) kinases (174). Imatinib received accelerated FDA (US 
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Food and Drug Administration) approval in 2001, and 5- and 6-year follow-up studies 
reported impressive response rates and outstanding estimated overall survival rates in 
CML patient cohorts receiving imatinib as initial therapy (175,176). Nevertheless, 
imatinib is observed to be less effective in the advanced phases of CML, disease 
persistence is detected in the majority of patients indicating that imatinib is unable to 




Figure 3. Domain organization of the Bcr (p160), Abl (p145) and Bcr-Abl (p210) proteins. 
Actin B: Actin binding domain; CaLB: Calcium-dependent lipid binding domain; DNA B: DNA 
binding domain; NLS: Nuclear localization signal; P: Proline-rich domain; Rac/GAP: Rac 
GTPase activating protein homology domain; Rho/GEF: Rho guanine-nucleotide-exchange 
factor homology domain; SH: Src homology domain. Major (M), minor (m) and micro (µ) 
breakpoint cluster regions in Bcr, and Tyr177 residue in Bcr-Abl are shown. Myr: myristoylation 
site. 
 
To overcome the problems experienced with imatinib, second generation small 
molecule inhibitors of Bcr-Abl have been developed. The novel inhibitors include the 
selective Abl inhibitor nilotinib (Tasigna/ AMN107), and the dual inhibitors of the Abl 
and Src kinases dasatinib (Sprycel/ BMS-354825) and bosutinib (Bosulif/ SKI-606). 
Similarly to imatinib, nilotinib and dasatinib also inhibit c-KIT and PDGFR (174). 
Nilotinib and dasatinib are currently approved as a frontline therapy of CML and as a 
second-line treatment option in CML patients who are resistant or intolerant to imatinib; 
while bosutinib has recently been approved to treat CML patients who failed on prior 
treatments with multiple Bcr-Abl inhibitors (178,179). Resistance against second 
generation inhibitors of Bcr-Abl also occurs but has yet been less characterized (177). 
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2.6.2. EGFR signaling in cancer and its small molecule inhibitors 
The Epidermal Growth Factor Receptor (EGFR/ErbB1/HER1) belongs to the ErbB 
subclass of the receptor tyrosine kinase (RTK) superfamily. ErbB receptors are 
physiologically expressed in various tissues of epithelial, mesenchymal and neuronal 
origins and play an essential role in embryogenesis. ErbBs are single-pass transmembrane 
receptors having an extracellular domain responsible for the binding of polypeptide 
ligands of the EGF (Epidermal Growth Factor) family and an intracellular region 
containing a tyrosine kinase catalytic domain. ErbB receptors homo-or heterodimerize 
upon ligand binding that results in activation of the intrinsic kinase domain and 
subsequent phosphorylation of tyrosine residues in the cytoplasmic tail. The 
phosphotyrosine residues serve as docking sites for adaptor proteins or enzymes with Src 
homology-2 (SH2) or phosphotyrosine-binding (PTB) domains, recruitment of which 
mediates the activation of multiple downstream signaling cascades involved in various 
cellular programs, such as proliferation, differentiation, survival, migration and adhesion. 
Under physiological conditions, ErbB receptor activity is tightly controlled by the spatial 
and temporal ligand accessibility (180,181). 
EGFR (and ErbB2/HER2/Neu as well) has been reported to be constitutively active in 
numerous cancer types including glioma, breast cancer, ovarian cancer, colorectal 
cancer (CRC), squamous-cell carcinoma of head and neck (SCCHN) and non-small 
cell lung cancer (NSCLC). Aberrant activation of EGFR was reported to result from 
autocrine ligand production or overexpression or mutation of the receptor itself and was 
associated with poor clinical outcomes (180). Accordingly, EGFR has intensively been 
pursued as a molecular drug target. Therapeutic inhibition of EGFR can be achieved by 
monoclonal antibodies (mAbs) that either neutralize ligands or target the extracellular 
ligand binding domain of the receptor thus preventing dimerization-mediated activation 
and causing receptor internalization. Another therapeutic option is the administration of 
small molecule inhibitors which target the intracellular tyrosine kinase domain of the 
receptor (181,182). Small molecule inhibitors of EGFR include gefitinib (Iressa/ 
ZD1839) and the second generation inhibitors vandetanib (Zactima/ ZD6474), pelitinib 
(EKB-569) and neratinib (HKI-272) (154,183). Second generation EGFR inhibitors are 
multi-kinase specific and/or irreversibly bind to the target receptor that is believed to 
ABCG2 and targeted anti-cancer drugs                                                 Csilla Hegedüs, PhD thesis 
 24
enable augmentation of drug efficacy and the targeting of multiple types of solid tumors. 
Vandetanib is a potent inhibitor of vascular endothelial growth factor receptor 2 and 3 
(VEGFR-2,3), and shows additional inhibitory activity against EGFR (184). Pelitinib 
covalently binds to and inhibits EGFR (185). Neratinib, another irreversible inhibitor of 
EGFR was synthesized on the chemical scaffold of pelitinib, and has additional inhibitory 
activity against ErbB2/HER2/Neu (186). Gefitinib, vandetanib, pelitinib and neratinib are 
presently under clinical evaluation or use either as monotherapy or in combination for a 
histologically diverse range of tumors, including lung cancer (183), breast cancer (187-
189) and colorectal cancer (190). Notably, resistance to small molecule inhibitors of 
EGFR has also been reported to occur in several cases and represents a major impediment 
to the successful management of the relevant solid tumors (183,191,192). 
 
2.7. Relevance of ABCG2 in resistance to small molecule kinase inhibitors applied 
in targeted cancer therapies 
Target-dependent and target-independent molecular mechanisms causing resistance 
to small molecule inhibitors of Bcr-Abl and EGFR have both been described. Point 
mutations in the kinase domain of Bcr-Abl and EGFR, overexpression of Bcr-Abl and 
engagement of redundant signaling molecules (such as increased signaling by Lyn kinase 
or the MET receptor kinase in CML and lung cancer, respectively) are currently 
recognized as causal factors of drug resistance in the relevant tumor types (174,177,181-
183,191,192). As small molecule kinase inhibitors have to pass the cell membrane to 
exert their intracellular kinase inhibitory action, involvement of the MDR-ABC efflux 
transporters has also been implicated in the emergence of drug resistance. On one hand, 
MDR-ABC proteins which are physiologically expressed at pharmacological tissue 
barriers might modify the bioavailability of the orally administered small molecule 
kinase inhibitors. On the other hand, exploiting the physiological protective function of 
the transporters, targeted cancer cells which overexpress MDR-ABC proteins might 
develop (multiple) drug resistance. Furthermore, the specific function of ABCG2 might 
also protect the cancer stem cell (CSC) population leading to replenishment of the 
tumor. ABCG2 has been shown to interact with numerous clinically relevant small 
molecule kinase inhibitors (Table 2). The current literature on these interactions has 
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recently been reviewed by us (193,194); therefore, here I focus on data regarding 
interaction between ABCG2 and small molecule inhibitors of Bcr-Abl or EGFR. 
Initially, data regarding the interaction of ABCG2 and imatinib were conflicting. 
Imatinib was reported to modulate the ATPase activity of ABCG2, which indicated that 
ABCG2 recognized and interacted with imatinib (195); however, at the time, imatinib 
had been recognized either as a substrate (196) or as an inhibitor (197) of the transporter. 
In subsequent reports, mostly published when our project had already been running, the 
ABCG2 ATPase modulatory effect of imatinib was confirmed (198,199), and ABCG2 
was shown to transport lower concentrations of imatinib and to confer in vitro cellular 
imatinib resistance (78,196,198). Parallelly, imatinib at higher doses was reported to 
reverse ABCG2-mediated cellular resistance to the ABCG2 substrates mitoxantrone 
(195), topotean and SN-38 (197) and to inhibit the ABCG2-mediated transport of 
mitoxantrone (196), pheophorbide a (200,201) and Hoechst 33342 (195,198). 
Information about the interaction of ABCG2 and second generation inhibitors of Bcr-Abl 
were scarce. Both nilotinib and dasatinib were suggested to be transported by ABCG2 
(198,202), and nilotinib was further shown to inhibit ABCG2-mediated Hoechst 33342 
transport (198). 
The first successful EGFR inhibitor gefitinib was characterized in detail with respect 
to its in vitro interaction with ABCG2. Gefitinib was shown to stimulate the ATPase 
activity of ABCG2 (195,203); however, similarly to imatinib, discrepancies soon 
emerged regarding the nature of the interaction between gefitinib and the transporter. 
Following the initial controversies concerning whether this compound is a substrate of 
ABCG2 or not (203-206), subsequent studies confirmed that ABCG2 transports lower 
concentrations of gefitinib and thereby causes in vitro cellular gefitinib resistance 
(203,204,207,208), while higher doses of gefitinib re-sensitize drug resistant cells to 
mitoxantrone, topotecan and SN-38 and inhibit ABCG2-mediated Hoechst 33342 and 
topotecan transport (195,206). The issue whether ABCG2 interacts with second 
generation inhibitors of EGFR has only been addressed in the case of vandetanib and the 
clinically irrelevant ABCG2 R482G variant (209). 
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3. AIMS 
Since at the very beginning of the first project presented in my thesis, data regarding 
the interaction of ABCG2 with imatinib were controversial, and no information was 
available about the interaction of ABCG2 and second generation inhibitors of Bcr-Abl, 
we aimed to 
 investigate whether imatinib can interfere with the ATPase activity of human 
wild-type ABCG2, 
 set up and characterize a Bcr-Abl+ K562 cellular model system showing stable 
overexpression of the human wild-type ABCG2 multidrug transporter, 
 clarify whether the function of human wild-type ABCG2 can influence the 
intracellular effects of imatinib, 
 applying the Sf9 insect membrane- and Bcr-Abl+ K562 cell-based model 
systems which we validated by the analysis of the ABCG2-imatinib 
interaction, perform a comparative biochemical characterization on the 
interaction profile between human wild-type ABCG2 and the second 
generation Bcr-Abl inhibitors nilotinib, dasatinib and bosutinib. 
In the second project presented in my thesis, using gefitinib as a well-characterized 
control, we set out to 
 screen the potential interaction between ABCG2 and the second generation 
EGFR inhibitors vandetanib, pelitinib and neratinib using Sf9 insect 
membranes containing human wild-type ABCG2, 
 explore whether ABCG2 influences the intracellular effects of vandetanib, 
pelitinib and neratinib in EGFR+ A431 cells showing stable overexpression of 
human wild-type ABCG2, 
 study whether vandetanib, pelitinib and neratinib are capable of inhibiting the 
function of human wild-type ABCG2, 
 investigate whether gefitinib exposure influences the expression of ABCG2, 
 elucidate the role of the PI3K/Akt signaling axis in the rapid regulation of 
ABCG2. 
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4. MATERIALS AND METHODS 
4.1. Materials 
All chemicals were obtained from Sigma-Aldrich, unless stated otherwise. The 
investigated small molecule inhibitors of Bcr-Abl and EGFR kinases were synthesized 
and validated by VICHEM Chemie (Budapest, Hungary). Acrylamide/Bis solution, 
TEMED and PVDF membranes were purchased from Bio-Rad Laboratories. Acetonitrile 
and water used in the HPLC-MS experiments were HPLC grade and were obtained from 
Sigma-Aldrich. Acetic acid was purchased from Reanal. Purospher STAR RP-18 
endcapped column (3 μm, 2 × 55 mm) was obtained from Merck. Human recombinant 
epidermal growth factor (hEGF) was purchased from Cell Signaling Technology. Alexa-
Fluor-conjugated antibodies, wheat germ agglutinin (WGA), TOPRO-3 and DAPI were 
obtained from Invitrogen. Ko143 was obtained from Tocris Bioscience. Phycoerythrin-
conjugated secondary antibodies were purchased from Beckman Coulter. 
 
4.2. Cell lines 
Stable human wild-type ABCG2 (referred to as ABCG2 hereafter) expressing 
derivatives of K562, A431 and PLB985 (PLB) cells were generated by retroviral 
transgene delivery by the laboratory of Katalin Német as described in detail previously 
(195,203,210). MDCKII cells stably expressing the N-terminally GFP-tagged version of 
human wild-type ABCG2 (referred to as GFP-ABCG2 hereafter) (211) were generated 
by the laboratory of Tamás Orbán, employing the Sleeping Beauty transposon-based 
transgene delivery system (212,213). Gefitinib resistant subclones of NCI-H1650 cells 
were generated by Kwak et al (214). Cell cultures were maintained in the appropriate 
medium (RPMI for K562, PLB and NCI-H1650 cells, α-MEM for A431 cells and D-
MEM for MDCKII cells, all media purchased from Gibco) supplemented with 10% heat-
inactivated fetal bovine serum (Gibco), 50 units/mL penicillin, 50 units/mL streptomycin 
and 5 mmol/L glutamine, at 37 °C in 5% CO2. Cells were regularly monitored for 
Mycoplasma infection with the MycoAlert® Mycoplasma Detection Kit (Lonza). Total 
and plasma membrane expression of ABCG2 was checked by Western blot using the 
anti-ABCG2 BXP-21 antibody (kind gift of Drs. George Scheffer and Rik Scheper) 
(139), and by flow cytometry using the anti-ABCG2 5D3 antibody (kind gift of Brian P. 
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Sorrentino) (70,215), respectively, as described in section 4.7. Specific ABCG2 function 
in the applied cell lines was routinely tested by Hoechst 33342 transport measurements 
(139) according to the protocol detailed in section 4.12. 
 
4.3. Fluorescent in situ hybridization 
In order to analyze bcr-abl chimeric genes in the applied K562 cell lines, fluorescent 
in situ hybridization (FISH) was performed by András Kozma using the universal FISH 
protocol of Q-BIOgene Molecular Cytogenetics. To visualize the genes of interest in the 
isolated nuclei of K562 or K562/ABCG2 cells, the Vysis LSI BCR/ABL Dual Color, 
Dual Fusion Translocation Probe (Abbott) was used. 
 
4.4. Heterologous expression of ABCG2 
To express human ABCG2 or GFP-ABCG2 in Spodoptera frugiperda (Sf9) insect 
cells, the baculovirus expression vector system was used. Baculovirus transfer vectors 
(pAcUW21-L) carrying ABCG2 or its GFP-tagged variant and recombinant 
baculoviruses (generated using the BaculoGold Transfection Kit, Pharmingen according 
to the manufacturer’s instructions) were generated by Csilla Laczka as described 
previously (41,211). 
Amplified viral stocks (1-2*108 pfu/mL) were used to infect Sf9 cells and to produce 
recombinant ABCG2 or GFP-ABCG2. 3*107/175 cm2 cell culture flask of Sf9 cells in 5 
mL insect cell culture media were incubated with 3 mL recombinant baculovirus 
supernatant for 1 hour at room temperatue. After addition of 15 mL insect cell culture 
media to the flasks, Sf9 cells were further incubated with the recombinant baculoviruses 
for 72 hours at 27 °C. Cells expressing the proteins of interest were then harvested and 
their membranes were isolated according to the protocol described in section 4.5.  
  
4.5. Membrane preparation procedure 
ABCG2-containing Sf9 membranes were isolated using the protocol described earlier 
(216), with minor modifications. 72 hours post-infection, Sf9 cells were harvested and 
were washed twice with ice cold washing buffer (50 mM TRIS pH=7.0, 300 mM 
mannitol, 50 µg/mL phenylmethylsulfonyl fluoride) at 4 °C. Cells were then collected in 
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TMEP buffer (50 mM TRIS pH=7.0, 50 mM mannitol, 2 mM EGTA-TRIS, 8 µg/mL 
aprotinin, 10 µg/mL leupeptin, 50 µg/mL phenylmethylsulfonyl fluoride, 2 mM 
dithiothreitol) and lysed and homogenized in a teflon glass tissue potter for 10 minutes on 
ice. Cellular debris was removed by centrifugation at 450 g for 10 minutes at 4 °C. 
Homogenization and centrifugation was repeated. The supernatant containing the 
membrane fragments was then transferred into ultracentrifuge tubes and was incubated 
with 2 mM random methylated beta cyclodextrin loaded with cholesterol (CycloLab) for 
20 minutes at 4 °C on a tube roller (217). After centrifugation at 45000 g for 60 minutes 
at 4 °C, the pellet containing the isolated membrane fragments was resuspended in TMEP 
buffer to obtain approximately 4-6 mg/mL total protein concentrations. Membrane 
samples were stored at -70 °C in aliquots until further analysis. 
 
4.6. Determination of protein concentrations 
Total protein concentration of the samples was determined by the modified Lowry 
method (218), using bovine serum albumin (BSA) solutions with known concentrations 
to obtain standard curves. 
Briefly, 5 µL of Sf9 membrane preparation samples was incubated in 1.5 mL Lowry 
reagent (0.19 M Na2CO3 in 1 M NaOH solution supplemented with 1% (v/v) 2% sodium 
tartrate solution and 1% (v/v) 1% CuSO4 solution) and 0.15 mL 1 N Folin-Ciocalteu’s 
phenol reagent for 45 minutes at room temperature. Absorbance of the samples was read 
at 660 nm (using the Perkin Elmer UV/Vis Spectrometer Lambda R). 
To determine total protein concentration of samples stored in sample buffer 
(disaggregating buffer, DB, see section 4.7 or Laemmli sample buffer, see section 4.11), 
2.5 or 5 µL samples were diluted in 1.5 or 2 mL distilled water, respectively. 20 µL 2% 
deoxycholate (DOC) solution was added to each sample. Following incubation for 15 
minutes at room temperature, samples were precipitated by addition of 750 µL 25% 
trichloro acetic acid (TCA) solution. Following centrifugation at 4000 g for 45 minutes at 
4 °C, precipitates were incubated in 1.5 mL Lowry reagent and 0.15 mL 1 N Folin-
Ciocalteu’s phenol reagent for 45 minutes at room temperature. Absorbance of the 
samples was read at 660 nm. 
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4.7. Immunodetection of ABCG2   
ABCG2 protein yields of the heterologous Sf9 expression system were estimated by 
Western blot. Sf9 membrane preparations with previously determined protein 
concentrations (see section 4.6) were diluted in disaggregating buffer (DB; 50 mM TRIS-
PO4 pH=6.8, 2% SDS, 2% β-mercaptoethanol, 2 mM EDTA pH=6.8, 20% glycerol, 
0.02% bromphenol blue), and 1-10 µg total proteins were loaded onto 10% Laemmli-type 
SDS gels. Gel electrophoresis and protein transfer onto PVDF membranes were carried 
out using standard methodology. Blots were developed using the monoclonal anti-
ABCG2 BXP-21 antibody at 125 ng/mL concentration. 
Total ABCG2 protein levels in the model cells applied were also measured by Western 
blot. 2-10*106 cells were collected in DB. After one freeze-thaw cycle, samples were 
sonicated and their protein concentrations were determined by the modified Lowry 
method as described in section 4.6. 10-50 µg total proteins were resolved using 10% 
Laemmli-type SDS gels. Gel electrophoresis and protein transfer onto PVDF membranes 
were carried out using standard methodology. Blots were developed using the 
monoclonal anti-ABCG2 BXP-21 antibody at 500 ng/mL concentration. 
 For visualization of the immunoblots, goat anti-mouse horseradish peroxidase-
conjugated secondary antibodies at 1:10000 or 1:20000 dilution (Jackson 
Immunoresearch) and the enhanced chemiluminescence (ECL) detection system were 
used (Amersham Biosciences/GE Healthcare). 
Cell surface ABCG2 expression in the model cells applied was followed by labeling 
with the monoclonal anti-ABCG2 5D3 antibody that recognizes an external epitope of the 
transporter (70,215). For flow cytometry measurements, 5D3 labeling was carried out 
using aliquots of 2-5*105 intact cells suspended in HPMI buffer (120 mM NaCl, 5 mM 
KCl, 400 μM MgCl2, 40 μM CaCl2, 10 mM HEPES, 10 mM NaHCO3, 10 mM glucose 
and 5 mM Na2HPO4) containing 0.5% bovine serum albumin (BSA). For indirect 
labeling, cells were incubated with 1 μg/mL 5D3 or 1 μg/mL mouse IgG2b (isotype 
control) in a final reaction volume of 100 μL for 45 minutes at 37 °C. After washing, 
either 3 μg/mL phycoerythrin (PE) - or 200x diluted Alexa-Fluor-647 (A647)-conjugated 
goat-anti mouse secondary antibodies were applied in 50 μL HPMI-0.5% BSA for 30 
minutes at 37 °C, and their fluorescence was determined at 488 nm excitation and 585/42 
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nm emission (FL2) or 635 nm excitation and 661/16 nm emission (FL4) wavelengths, 
respectively, in a FACSCalibur flow cytometer (BD Biosciences). For direct labeling, 
cells were incubated with 2 µg/mL Alexa-Fluor-647 (A647)-conjugated 5D3 or isotype 
control antibodies in a final reaction volume of 100 μL for 45 minutes at 37 °C, and their 
fluorescence was determined at 635 nm excitation and 661/16 nm emission (FL4) 
wavelengths. For the ABCG2 localization experiments, 1% paraformaldehyde (PFA)-
containing solution was applied for 10 minutes at 37 °C for fixation before the above 
mentioned labeling procedures. 
The effect of drugs on the conformation and the related changes in the 5D3 binding 
affinity of ABCG2 (‘5D3-shift’ phenomenon introduced in (215)) were investigated 
using the same labeling protocol, except that following a pre-incubation for 5 minutes at 
37 °C, drugs were also present throughout labeling with 5D3 or mouse IgG2b in HPMI 
buffer. In these experiments, 1 µM Ko143 was used to achieve maximum 5D3 binding of 
ABCG2. Except for PFA-fixed samples, TOPRO-3 (in case of applying PE fluorophore-
conjugates) or propidium iodide (in case of applying A647 fluorophore-conjugates) 
staining was also performed as the final step of the labeling procedure, to allow exclusion 
of dead cells. 
For 5D3 labeling of cells for confocal microscopy studies, 4*104 cells/well were 
seeded onto 8-well Nunc Lab-Tek II chambered coverglass (Nalge Nunc International) 
and were grown for 48 hours in 400 μL/well complete medium. Following multiple 
washing steps with 37 °C Dulbecco’s modified phosphate buffered saline (DPBS) cells 
were fixed in 1% PFA in DPBS for 15 minutes at 37 °C. Blocking was achieved by 
incubation of cells with DPBS-0.5% BSA for 1 hour at room temperature. 5D3 or mouse 
IgG2b was applied at a final concentration of 2 μg/mL in DPBS-0.5% BSA for 1 hour at 
room temperature. Following three washing steps with DPBS, Alexa-Fluor-488 
conjugated goat anti-mouse secondary antibodies were administered at a dilution of 1:250 
in blocking buffer for 1 hour at room temperature. After washing with DPBS, samples 
were stored at 4 °C in DPBS containing 0.46 mM sodium-azide. For visualization of 
nuclei, cells were stained with 10 μM DAPI for 10 minutes at room temperature. Images 
were captured with an Olympus IX-81/FV500 laser scanning confocal microscope and 
analyzed by the FluoView 4.7 software. 
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4.8. Measurement of the ATPase activity of ABCG2 
Vanadate-sensitive ATPase activity was measured using membrane fragments isolated 
from ABCG2- or GFP-ABCG2-expressing Sf9 insect cells (see section 4.4 and 4.5 for 
details) by determining the liberation of inorganic phosphate from ATP with a 
colorimetric reaction (41,216). The reaction pre-mix (kept on ice) containing 10 µg/mL 
membrane protein and the investigated small molecule inhibitors, 1 µM quercetin 
(positive control), 0.5 µM Ko143 (negative control) or 1.3 mM sodium orthovanadate in 
reaction buffer (40 mM MOPS–TRIS pH=7.0, 50 mM KCl, 2 mM dithiothreitol, 500 µM 
EGTA–TRIS, 5 mM sodium-azide, 1 mM ouabain) was incubated at 37 °C for 5 minutes 
in shaker water bath. The reaction was started with the addition of 3.3 mM MgATP and 
the reaction mixture (in a final volume of 150 µL) was further incubated at 37 °C for 20 
minutes. The reaction was stopped by addition of 100 µL 5% SDS solution. The 
subsequent colorimetric reaction was performed at room temperature. Samples were 
supplemented with 300 µL phosphate reagent (2.5 M H2SO4, 1% ammonium molybdate, 
0.014% antimony potassium tartrate), 750 µL 20% acetic acid and 150 µL 1% ascorbic 
acid, and were incubated for 30 minutes at room temperature. Optical densities were read 
at 880 nm in a Perkin Elmer UV/Vis Spectrometer Lambda R. K2HPO4 solutions were 
used to obtain calibration curves, measurements were performed in duplicates. 
  
4.9. Cellular viability assays 
To measure the cellular toxicity of the investigated Bcr-Abl inhibitors, 1*105/well 
K562 or K562/ABCG2 cells (growing in suspension culture) were seeded in 1 mL/well 
complete medium in 24-well plates. Cells were exposed to increasing doses of Bcr-Abl 
inhibitors in the absence or the presence of the specific ABCG2 inhibitor FTC (applied at 
5 μM final concentration) for 48 hours at 37 °C in 5% CO2. Cellular viability in 500 μL 
thoroughly suspended samples was determined by cellular staining with 50 nM TOPRO-
3 and subsequent flow cytometry analysis. The assay was carried out in duplicates. 
Cellular viability of drug-treated A431 and NCI-H1650 cells and their ABCG2-
expressing counterparts (growing in monolayer culture) was determined by the MTT (3-
[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium) assay. 4*103 cells/well were seeded 
in 100 μL/well complete medium in 96-well plates, and were let to adhere. The following 
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day, drugs were added in 100 μL medium, to achieve the indicated final concentrations in 
the 200 μL final volume. Cells were incubated with drugs for 72 hours at 37 °C in 5% 
CO2, and then were stained with 0.5 mg/mL MTT dissolved in PBS. Following 
incubation for 4 hours at 37 °C in 5% CO2, the formed formazan crystals were 
solubilized by addition of 100 μL of 9:1 isopropanol-hydrochloric acid solution. 
Absorbance was measured at 540 nm using a Perkin Elmer Victor X3 2030 Multilabel 
Plate Reader. Experiments were carried out in quadruplicates. Where appropriate, IC50 
values were determined using the Prism software (GraphPad Software, Inc.) by fitting 
curves using nonlinear least-squares regression in a sigmoidal dose-response model with 
variable slope. 
 
4.10. Measurement of hemoglobin production 
2*105/mL K562 and K562/ABCG2 cells were exposed to 2 µM FTC or 0.5 µM 
imatinib administered as a single agent or in combination for 72 hours at 37 °C in 5% 
CO2. Cellular viability in 500 μL thoroughly suspended samples was determined by 
cellular staining with 50 nM TOPRO-3 and subsequent flow cytometry analysis. The 
remaining cells were washed with PBS and then were collected in PBS-1% Nonidet-P40 
solution. Samples were sonicated and centrifuged at 11000 g for 35 minutes at 4 °C. 
Hemoglobin content in the supernatant was determined by benzidine-staining (219) 
performed in duplicates for each sample. Briefly, 100 µL 1% benzidine solution in 90% 
acetic acid and 100 µL 1% hydrogen peroxide solution was added to 25 µL of the 
supernatant fractions. Following incubation for 20 minutes at room temperature, 1 mL 
10% acetic acid was administered to each sample and absorbance at 512 nm was 
determined in a Perkin Elmer UV/Vis Spectrometer Lambda R. Hemoglobin 
concentration of the samples was calculated using bovine hemoglobin calibration curves. 
Data were normalized to the number of live cells in each sample, and were plotted 
relative to the amount of hemoglobin measured in vehicle-treated control samples. 
 
4.11. Detection of kinase phosphorylation by Western blot 
In order to test the intracellular efficiency of the investigated Bcr-Abl inhibitors at the 
target kinase site, 4*105/mL K562 or K562/ABCG2 cells were seeded in Petri dishes. 
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Cells were exposed to 500 nM imatinib, 25 nM nilotinib, 5 nM dasatinib or 50 nM 
bosutinib in the absence or in the presence of 5 μM FTC for 48 hours at 37 °C in 5% 
CO2. 
In order to test the intracellular efficiency of the investigated inhibitors of EGFR, 
PI3K and mTOR at the target or downstream kinase sites, 7.5*105/mL A431 or 
A431/ABCG2 cells were seeded in serum-free or complete media in 6-well plates and 
were let to adhere. After 16 hours, cells were either stimulated with 20 ng/mL hEGF for 
15 minutes and then were exposed to the small molecule inhibitors at the indicated 
concentrations for additional 15 minutes at 37 °C in 5% CO2, or were treated with 100 
nM wortmannin for 90 minutes at 37 °C in 5% CO2. 
Protein samples were prepared according to the protocol described previously (220), 
with minor modifications. Following washing with ice cold PBS, cells were collected in 
lysis buffer (50 mM TRIS-HCl, 150 mM NaCl, 1 mM EDTA-Na, 1 mM EGTA-Na, 1 % 
Nonidet-P40) containing various inhibitors of phosphatase enzyme activities (40 mM β-
glycerophosphate, 1 mM p-nitrophenyl-phosphate, 20 mM sodium fluoride, 1 mM 
sodium orthovanadate, 10 mM sodium pyrophosphate) and various inhibitors of protease 
enzyme activities (10 mM benzamidine, 10 µg/mL antipain, 10 µg/mL aprotinin, 10 
µg/mL leupeptin, 10 µg/mL pepstatin A, 1 mM phenylmethylsulfonyl fluoride). After 10 
minutes shaking at 4 °C, cellular debris was removed by centrifugation at 17000 g for 12 
minutes at 4 °C. The supernatant containing the cellular proteins was diluted in Laemmli 
sample buffer (62.5 mM TRIS-HCl pH=6.8, 2% SDS, 10% glycerol, 2% β-
mercaptoethanol, 0.02% bromphenol blue, 25 mM dithiothreitol; final concentrations are 
indicated). Samples were boiled for 5 minutes and were stored at -20 °C until further 
analysis. Protein concentration of the samples was determined by the modified Lowry 
method, as detailed in section 4.6. 
20-40 µg total proteins were resolved using Laemmli-type SDS gels. Gel 
electrophoresis and protein transfer onto PVDF membranes were carried out using 
standard methodology. Blots were probed with the following antibodies: phospho-Bcr 
(Tyr177) (Cell Signaling Technology) at 1:1000 dilution, 0.2 µg/mL c-Abl (24-11) (Santa 
Cruz Biotechnology), 0.5 µg/mL c-Abl (K-12) (Santa Cruz Biotechnology), phospho-
EGFR (Tyr1068) at 1:4000 dilution (Cell Signaling Technology), 0.4 µg/mL phospho-
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Akt 1/2/3 (Ser 473) (Santa Cruz Biotechnology), 0.4 µg/mL phospho-p70S6 kinase alpha 
(Thr 389) (Santa Cruz Biotechnology) and 0.5 µg/mL beta actin. For visualization of the 
immunoblots, horseradish peroxidase-conjugated secondary antibodies at 1:10000 or 
1:20000 dilution (Jackson Immunoresearch) and the enhanced chemiluminescence (ECL) 
detection system were used (Amersham Biosciences/GE Healthcare). 
 
4.12. Fluorescent dye accumulation and uptake studies 
Intracellular accumulation of the Hoechst 33342 dye was followed real-time using the 
Perkin Elmer Luminescence Spectrometer LS 50B at 350 nm excitation and 460 nm 
emission wavelengths, as described previously (139). Briefly, 5*105 parental or ABCG2-
expressing cells suspended in 2 mL HPMI buffer (120 mM NaCl, 5 mM KCl, 400 μM 
MgCl2, 40 μM CaCl2, 10 mM HEPES, 10 mM NaHCO3, 10 mM glucose and 5 mM 
Na2HPO4) were pre-incubated at 37 °C for 3-6 minutes. Cells were then incubated with 1 
µM Hoechst 33342 for additional 7-8 minutes followed by the administration of the 
specific ABCG2 inhibitors 1 µM Ko143 or 2 µM FTC. As a last step, for standardization, 
membrane permeabilization and subsequent full cellular staining was achieved by 
incubation of cells with 10 µM digitonin. The kinetics of Hoechst 33342 accumulation 
was analyzed with the FL WinLab (Perkin Elmer) software. Transport activity of ABCG2 
was calculated as (Fi-Fo)/Fi*100 (221); where F0 is the rate of dye accumulation in the 
absence of an ABCG2 inhibitor and Fi is the rate of dye accumulation in the presence of 
a specific ABCG2 inhibitor. The impact of the investigated small molecule inhibitors on 
the Hoechst 33342 transport capacity of ABCG2 was followed using the same approach. 
After pre-incubation of the ABCG2-expressing cells at 37 °C in HPMI buffer, cells were 
incubated with 1 µM Hoechst 33342 for 7-8 minutes (Fo), then co-incubated with 
Hoechst 33342 and the investigated small molecule inhibitor administered at a certain 
concentration for 4-5 minutes (Fx). Finally, cells were co-incubated with Hoechst 33342, 
the investigated compound and 1 µM Ko143 or 2 µM FTC (Fi) for another 3-5 minutes. 
ABCG2 transport activities under the different conditions were calculated with the FL 
WinLab software and ABCG2 inhibitory effect of the investigated small molecule 
inhibitors relative to the Ko143- or FTC-mediated maximum inhibition was calculated as 
(Fx-F0)/(Fi-F0)*100 (195). 
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The uptake of mitoxantrone (MX) was measured by flow cytometry (139). 2*105 cells 
were washed and resuspended in HPMI buffer. Cells were pre-incubated in the absence 
or the presence of the specific ABCG2 inhibitor 1 µM Ko143 for 5 minutes at 37 °C in 
shaker water bath. The transport reaction was started by addition of 2 µM MX in a final 
reaction volume of 200 µL. Following incubation with MX for 30 minutes at 37 °C, cells 
were washed with 500 µL ice cold PBS and were resuspended in 200 µL ice cold PBS 
containing 12.5 µg/mL propidium iodide. Cells were kept on ice until flow cytometry 
analysis. To investigate the effect of small molecule inhibitors on the MX transport 
capacity of ABCG2, 2*105 ABCG2-expressing cells in HPMI buffer were pre-incubated 
in the absence or in the presence of the investigated drug and 1 µM Ko143 administered 
alone or in combination for 5 minutes at 37 °C in shaker water bath. Cells were then 
incubated with 5 µM MX for 30 minutes at 37 °C. Cells were then washed and 
resuspended in ice cold PBS-12.5 µg/mL propidium iodide solution. Cells were kept on 
ice until flow cytometry analysis. MX fluorescence in live cells was analyzed in a 
FACSCalibur flow cytometer (BD Biosciences) at 635 nm excitation and 661/16 nm 
emission (FL4) wavelengths. 
 
4.13. Determination of the intracellular accumulation of the investigated Bcr-Abl 
inhibitors by HPLC-MS 
4*105/mL K562 or K562/ABCG2 cells were exposed to 25 nM nilotinib, 5 nM 
dasatinib or 10 nM bosutinib at 37 ºC for 60 minutes. After incubation, cells were 
collected in 5 mL ice-cold PBS. Cells were kept on ice throughout the sample preparation 
procedure. Following three washing steps with 5 mL PBS, cells were precipitated with 
500 µL acetonitrile containing 30 nM imatinib as an internal standard. After 
centrifugation at 8000 g for 5 minutes, the supernatant was transferred into eppendorf 
tubes and acetontirile was evaporated in a heated vacuum concentrator centrifuge 
(UNIVAPO 100 H, UniEquip). HPLC-MS analysis of the samples was performed by the 
laboratory of Zoltán Takáts. Nilotinib, dasatinib, bosutinib and imatinib were separated 
using a RP-18 column on a XLC binary HPLC pump system (Jasco International). 20 µL 
of reconstituted sample was injected; flow rate of HPLC eluent was set to 200 µL/min. 
Mobile phases used were: (A) 0.1% acetic acid in 100 mM ammonium acetate buffer and 
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(B) 0.1% acetic acid in acetonitrile. The total HPLC run time was 9 min, using the 
following gradient: 0–1 min.: 80% A, 1-6 min.:  5% A, 6-7 min.: 5% A,  7-9 min.: 80% 
A. The Bcr-Abl inhibitors were detected using a TSQ Quantum Discovery (Thermo 
Finnigan) triple quadrupole mass spectrometer operated in positive ion electrospray 
mode. Protonated molecular ions of analytes were detected in multiple reaction 
monitoring (MRM) mode using m/z 530289 and m/z 530261 fragmentation channel 
for nilotinib, m/z 488232 and m/z 488401 for dasatinib, m/z 530141 and m/z 
530113 for bosutinib and m/z 494217 and m/z 494394 for the internal standard 
imatinib. Amount of Bcr-Abl inhibitors in the samples were calculated from the 
respective Bcr-Abl inhibitor calibration curves and were normalized to the amount of 
imatinib. Experiments were carried out in duplicates. 
 
4.14. Determination of the subcellular distribution of GFP-ABCG2 by confocal 
microscopy 
To study subcellular distribution of GFP-ABCG2 in polarized cells, 2*104 
MDCKII/GFP-ABCG2 cells/well were seeded onto Nunc Lab-Tek II chambered 
coverglass (Nalge Nunc International) and were grown for 5 days. Following treatment 
with 100 nM wortmannin, 10 nM rapamycin or 10 µM rapamycin for 90 minutes at 37 
°C, cells were fixed with 4% PFA and were stained with 5 μg/mL Alexa-Fluor-633-
conjugated wheat germ agglutinin (WGA) and 1 μM DAPI. Subcellular distribution of 
GFP-ABCG2 relative to the apical marker WGA was evaluated by confocal microscopy. 
Images were captured with an Olympus IX-81/FV500 laser scanning confocal 
microscope and analyzed by the FluoView 4.7 software. 
 
4.15. Data analysis 
All experiments were repeated at least two times and mean +/- SD or SE values or 
representative images are presented. Differences were determined using Student’s t test at 
95% confidence interval. 
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5. RESULTS 
5.1. Interaction of ABCG2 and small molecule inhibitors of Bcr-Abl 
At the beginning of the first project presented in my thesis, literature data regarding 
the interaction between the ABCG2 multidrug transporter and the first successful Bcr-
Abl inhibitor imatinib were conflicting. It was clear that ABCG2 recognized and 
interacted with imatinib (195); however, imatinib had initially been described either as a 
substrate (78,196) or as an inhibitor (197) of the transporter. Data regarding interaction of 
ABCG2 with newly developed second generation Bcr-Abl inhibitors were not available 
at the time. Therefore, besides aiming to clarify the nature of the interaction between 
imatinib and ABCG2, we also decided to investigate whether ABCG2 interacted with the 
novel Bcr-Abl inhibitors nilotinib, dasatinib and bosutinib (Table 3). 
 
  Imatinib Nilotinib Dasatinib Bosutinib 
Aliases 
Gleevec/           
STI-571 
Tasigna/       
AMN107 
























Ph + ALL, 
 CML 
 
Table 3. Bcr-Abl inhibitors investigated in this study. C-KIT: Stem cell factor receptor; 
PDGFR: Platelet-derived growth factor receptor; Ph+ ALL: Philadelphia positive acute 
lymphoid leukemia; ASM: Advanced solid malignancies; CEL: Chronic eosinophil leukemia; 
CML: Chronic myeloid leukemia; GIST: Gastrointestinal stromal tumor; HES: 
Hypereosinophilic syndrome; MDS/MPD: Myelodysplastic syndrome/myeloproliferative 
disorders.  
 
5.1.1. Effect of imatinib on the ATPase activity of ABCG2 
In the first set of experiments, we aimed to give detailed characterization of the 
interaction between ABCG2 and imatinib. ABCG2 expressed in Sf9 insect membranes 
generates high membrane ATPase activity (41). Many substrates of ABCG2 can 
stimulate the ATPase activity of the transporter, and modulation (stimulation or 
inhibition) of the ABCG2 ATPase indicates interaction between the drug and the protein 
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(41,127,222). Therefore, as a first step, we studied whether imatinib could modulate the 
ATPase activity of ABCG2. Membrane fragments were isolated from insect Sf9 cells 
overexpressing ABCG2 as described in section 4.5. Cholesterol enrichment of the 
cholesterol-poor insect membranes was suggested to improve the sensitivity of the 
ATPase assay (217), therefore throughout this study we also performed cholesterol 
loading of the membrane preparations. As shown in Fig.4, ABCG2 exhibited a relatively 
high basal ATPase activity in the absence of any compounds. Imatinib decreased this 
basal ATPase activity in a concentration-dependent manner, suggesting that ABCG2 
indeed interacted with this drug. We also measured the effect of imatinib on the drug-
stimulated ATPase activity of ABCG2. In this experimental setup, high turnover of the 
ABCG2 ATPase was triggered by administration of quercetin, which is a high affinity 
substrate for the transporter (223). As expected (222), imatinib decreased the quercetin-
stimulated ATPase activity of ABCG2 (Fig. 4). Collectively, these data support the 
interaction of ABCG2 and imatinib; however, cannot give a clear-cut picture about the 
nature of this interaction. While specific ABCG2 inhibitors significantly decrease the 
high basal ABCG2 ATPase activity in isolated Sf9 membrane fragments (139,223), 
inhibition of the basal ABCG2 ATPase in a similar experimental system has also been 
reported in the case of ABCG2 substrates which are transported at a lower rate (41,139). 
Therefore, the ATPase assay cannot necessarily distinguish between ABCG2 substrates 
and inhibitors (127,222). 
 
Figure 4. Modulation 
of the ATPase activity of 
ABCG2 by imatinib. 
Concentration-dependent 
effect of imatinib on the 
basal and the stimulated 
(with 1 µM quercetin) 
ATPase activity of 




ABCG2. Mean ± SE 
values of three 
independent experiments 
(each performed in 
duplicates) are shown. 
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5.1.2. Characterization of the Bcr-Abl+ K562 and K562/ABCG2 cell lines 
In order to reveal whether the ABCG2-imatinib interaction suggested by the ATPase 
measurements is also relevant in a cellular context, and to clarify whether or not imatinib 
is a substrate of ABCG2, we generated and characterized a Bcr-Abl+ K562 cell based 
model system. K562 was the first CML-derived cell line which showed a persistent 
positive Philadelphia chromosome after prolonged in vitro culturing (224). K562 cells 
express the 210 kDa Bcr-Abl fusion protein bearing tyrosine kinase activity (225-227), 
and therefore are sensitive to inhibition of this kinase (228). K562 cells stably expressing 
human wild-type ABCG2 were generated using retroviral transgene delivery (210), by 
the laboratory of Katalin Német. Chimeric bcr-abl genes in the parental K562 and 
K562/ABCG2 cells were visualized by FISH. As shown in Fig. 5, the K562 cells applied 





Total expression levels of the ABCG2 protein in the K562 cells applied were 
measured by Western blot (Fig. 6A), whereas cell surface levels of the transporter were 
studied by labeling with the 5D3 antibody followed by flow cytometry analysis (Fig. 6B). 
As documented, K562/ABCG2 cells showed strong total and plasma membrane ABCG2 
protein expression. In contrast, no endogenous ABCG2 transporter expression could be 
detected in the parental K562 cells (Fig. 6A-B).  
Specific function of the ABCG2 transporter in the model cells was tested by following 
the intracellular accumulation of the Hoechst 33342 dye. Hoechst 33342 passively 
permeates the cell membrane and its fluorescence intensity significantly increases upon 
Figure 5. Chimeric bcr-abl 
genes in K562 and K562/ABCG2 
cells visualized by fluorescent in 
situ hybridization. Slides were 
prepared from isolated nuclei of 
1*106 K562 or K562/ABCG2 cells. 
The genes c-abl located on 
chromosome 9 (red), bcr located 
on chromosome 22 (green) and the 
chimeric gene bcr-abl located on 
chromosome 22 (yellow) were 
visualized by hybridization of 
fluorescently-labeled specific 
probes. Nuclei were counterstained 
with DAPI (blue). 
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its binding to DNA. Hoechst 33342 is a transported substrate of ABCG2 (139,229). As 
the increase in Hoechst 33342 fluorescence directly reflects the rate of intracellular dye 
accumulation, real-time detection of cellular Hoechst 33342 uptake has been suggested to 
allow for sensitive, rapid and reliable evaluation of ABCG2 transport function (139,211). 
Hoechst 33342 is also a substrate for ABCB1 (230), another key transporter involved in 
multidrug resistance; however, contribution of this protein to cellular Hoechst 33342 
extrusion can be excluded by using the ABCG2 specific inhibitor Ko143.  
 
Figure 6. ABCG2 expression and function in K562 and K562/ABCG2 cells. (A) Total 
ABCG2 protein levels of (lane 1) K562 and (lane 2) K562/ABCG2 cells were determined by 
Western blot using the BXP-21 antibody. (B) Cell surface expression of ABCG2 in K562 and 
K562/ABCG2 cells was measured by flow cytometry using the Alexa-Fluor-647-conjugated- 
IgG2b (isotype control, IT) or -5D3 antibodies (C) Specific ABCG2 function in K562 and 
K562/ABCG2 cells was followed by real-time spectrofluorometric detection of the cellular 
accumulation of the ABCG2 substrate dye, Hoechst 33342. Representative images of at least 
three independent experiments are shown. 
 
As shown in Fig. 6C, the uptake of Hoechst 33342 resulted in a rapid initial increase 
in cellular fluorescence in both K562 and K562/ABCG2 cells, which can partially be 
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explained by nuclear staining of dead cells and the increase of Hoechst 33342 
fluorescence in the membrane lipid phase (139). However, in K562/ABCG2 cells, the 
rate of further Hoechst 33342 uptake and the subsequent increase of fluorescence 
intensity were much slower than those measured in K562 cells, most probably due to 
active ABCG2-mediated dye extrusion. Indeed, when ABCG2 function was blocked by 
the administration of Ko143, the rate of Hoechst influx in K562/ABCG2 cells became 
similar to that observed in K562 cells. In correlation with the ABCG2 expression data 
(Fig. 6A-B), we could not detect any endogenous ABCG2 function in the parental K562 
cells, since we measured similar Hoechst 33342 dye uptake rates both in the absence and 
in the presence of Ko143 (Fig. 6C). 
 
5.1.3. ABCG2 confers cellular resistance to imatinib 
Imatinib displays a growth inhibitory effect on tumor cells expressing Bcr-Abl (170-
172), and induces their apoptosis through dephosphorylation of Bcr-Abl and subsequent 
inhibition of its kinase activity and downstream signaling (228,231,232). 
 
 
Figure 7. Cellular toxicity of imatinib in K562 and K562/ABCG2 cells. (A) 1*105/mL cells 
were exposed to increasing concentrations of imatinib for 48 hours. (B) To determine the specific 
effect of ABCG2, 4*105/mL cells were exposed to 0.5 µM imatinib in the absence or presence of 1 
µM Ko143 for 48 hours. The number of viable cells was determined by TOPRO-3 staining and 
subsequent flow cytometry analysis. Data were normalized to the number of viable cells 
measured in vehicle-treated samples. Mean ± SE values of three or two independent experiments 
(each performed in duplicates) are shown, respectively. 
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In the next set of experiments, we compared the toxicity of imatinib in K562 and 
K562/ABCG2 cells. After a 48-hour drug exposure, imatinib significantly decreased the 
viability of K562 cells in a concentration dependent manner. In contrast, K562/ABCG2 
cells displayed resistance to imatinib (Fig. 7A), which could be fully reverted by blocking 
the function of the transporter by Ko143 (Fig. 7B). The observed specific ABCG2-
mediated decrease of the intracellular cytotoxic efficiency of imatinib strongly supports 
the previous findings of others (78,196) suggesting that this drug is actively extruded by 
ABCG2. 
 
5.1.4. ABCG2 function prevents imatinib-induced erythroid differentiation in 
K562 cells 
Besides inducing apoptosis, imatinib also triggers erythroid differentiation of K562 
cells (228,232). As a next step, we studied whether ABCG2 function also prevented 
imatinib-induced erythroid differentiation of K562 cells. K562 and K562/ABCG2 cells 
were exposed to 0.5 µM imatinib in the absence or the presence of the specific ABCG2 
inhibitor FTC for 72 hours. Hemoglobin content of the live cells was determined by 




As shown in Fig. 8, imatinib treatment resulted in an almost 12-fold elevation of 
hemoglobin levels in K562 cells as compared to the vehicle-treated control cells. In 
Figure 8. Imatinib-induced 
hemoglobin production of K562 
and K562/ABCG2 cells. 2*105/mL 
cells were exposed to 2 µM FTC or 
0.5 µM imatinib administered as a 
single agent or in combination for 
72 hours. Hemoglobin production 
of the cells was determined by 
benzidine-staining and subsequent 
spectrophotometric analyis 
performed in duplicates for each 
sample. Data were normalized to 
the number of live cells in each 
sample, and were plotted relative 
to the amount of hemoglobin 
measured in vehicle-treated control 
samples. Mean ± SE values of two 
independent experiments are 
shown. 
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contrast, only a slightly increased hemoglobin production could be observed in the case 
of imatinib-treated K562/ABCG2 cells. When cells were co-incubated with imatinib and 
FTC, similarly high hemoglobin levels could be detected in both K562 and 
K562/ABCG2 cells. The finding that the presence of the functional ABCG2 protein can 
also restrict the cellular effect of imatinib on the process of erythroid differentiation in 
K562 cells further implies that this compound is a substrate for the ABCG2 transporter. 
 
5.1.5. Intracellular action of the second generation Bcr-Abl inhibitors nilotinib 
and dasatinib, but not that of bosutinib is restricted by ABCG2-mediated active 
efflux 
In the experiments described above, the K562 cell based model system generated by 
us proved to be applicable to investigate whether ABCG2 function resulted in decreased 
intracellular efficiency of Bcr-Abl inhibitors, a phenomenon which strongly suggests 
active ABCG2-mediated transport of the drugs. In the next series of measurements, we 
therefore compared the cellular toxicities of the newly developed Bcr-Abl inhibitors 
nilotinib, dasatinib and bosutinib in K562 and K562/ABCG2 cells (Fig. 9). 
Cells were incubated with the indicated drugs for 48 hours, and then were stained with 
TOPRO-3 in order to distinguish the population of live and dead cells. K562 cells 
showed sensitivity to increasing nanomolar concentrations of nilotinib (Fig. 9A), 
dasatinib (Fig. 9B) and bosutinib (Fig, 9C). In the case of nilotinib and dasatinib, 
however, we measured decreased drug sensitivity of K562/ABCG2 cells (Fig. 9A-B, 
respectively), which could be fully reversed by FTC-mediated specific pharmacological 
inhibition of ABCG2 function. In contrast, bosutinib was similarly effective in killing 
both K562 and K562/ABCG2 cells (Fig. 9C). 
To explore the molecular basis of the measured cellular toxicities of nilotinib, 
dasatinib and bosutinib, we studied the phosphorylation pattern of their target kinase Bcr-
Abl in K562 and K562/ABCG2 cells by Western blot. Imatinib, which was reported to 
induce apoptosis of Bcr-Abl positive cells via dephosphorylation of Bcr-Abl, inhibition 
of its kinase activity and subsequent inhibition of downstream signaling (228,231,232), 
was used as a positive control. The concentrations of the Bcr-Abl inhibitors were chosen 
according to the cellular toxicity measurements detailed above (Fig. 7 and 9). 
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Cells were exposed to Bcr-Abl inhibitors in the absence or the presence of FTC for 48 
hours. Phosphorylation of Bcr-Abl was probed using an antibody which recognizes the 
kinase when it is phosphorylated at Tyr177. As shown in Fig. 10, control K562 and 
K562/ABCG2 cells revealed high levels of constitutively phosphorylated Bcr-Abl, which 
is in accordance with the literature data (228). Exposure to all the investigated Bcr-Abl 
inhibitors resulted in decreased phospho-Bcr-Abl levels in K562 cells, and these 
phosphorylation patterns were similar both in the presence and in the absence of FTC. 
(Incubation of the cells with FTC alone had no impact on the phosphorylation of Bcr-
Abl, data not shown.) In contrast, K562/ABCG2 cells treated with imatinib, nilotinib or 
dasatinib displayed high phospho-Bcr-Abl protein levels, which were comparable to the 
phospho-Bcr-Abl protein level detected in untreated K562/ABCG2 cells. However, when 
K562/ABCG2 cells were simultaneously treated with the Bcr-Abl inhibitors imatinib, 
Figure 9. Cellular toxicity of nilotinib, 
dasatinib and bosutinib in K562 and 
K562/ABCG2 cells. 1*105/mL cells were 
incubated with increasing concentrations 
of (A) nilotinib, (B) dasatinib or (C) 
bosutinib in the absence or in the presence 
of 5 µM FTC for 48 hours. The number of 
viable cells was determined by TOPRO-3 
staining and subsequent flow cytometry 
analysis. Data were normalized to the 
number of viable cells measured in vehicle-
treated samples. Mean ± SE values of at 
least three independent experiments (each 
performed in duplicates) are shown. 
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nilotinib or dasatinib and FTC, a pronounced decrease in phospho-Bcr-Abl levels could 
be measured. Notably, co-treatment of K562/ABCG2 cells with these Bcr-Abl inhibitors 
and FTC resulted in similar levels of phosphorylated Bcr-Abl to those measured in K562 
cells. Bosutinib treatment of K562/ABCG2 cells caused a slight decrease in phospho-
Bcr-Abl levels both in the absence and in the presence of FTC. 
 
 
Figure 10. Phosphorylation of Bcr-Abl kinase in Bcr-Abl inhibitor-treated K562 and 
K562/ABCG2 cells. 4*105/mL cells were treated with 500 nM imatinib, 25 nM nilotinib, 5 nM 
dasatinib or 50 nM bosutinib in the absence or in the presence of 5 µM FTC for 48 hours. Cell 
lysates were prepared and 40 µg protein extracts were probed for phosphorylation of Bcr-Abl at 
Tyr177 by Western blot. Sample loading was checked by Coomassie Brilliant Blue staining of the 
gels (data not shown). A representative image of two independent experiments is shown. 
 
To check sample loading for the measurement presented in Fig. 10, first we performed 
Coomassie Brilliant Blue staining of the gels (data not shown). In addition, we developed 
the blots using the anti-c-Abl (K-12) antibody in order to visualize total Bcr-Abl protein 
levels in the samples (Fig. 11). The epitope of anti-c-Abl (K-12) maps within the kinase 
domain of the human c-Abl kinase, thus this antibody recognizes both the 210 kDa 
chimeric Bcr-Abl and the 145 kDa c-Abl proteins. Interestingly, we found that the 48-
hour exposure of K562 cells to the investigated Bcr-Abl inhibitors decreased the levels of 
the Bcr-Abl fusion kinase, which was most pronounced in the case of nilotinib and 
dasatinib treatment (Fig. 11). This effect was completely abolished by the presence of 
functional ABCG2 as shown in the case of K562/ABCG2 cells treated with imatinib, 
nilotinib or dasatinib. When the function of ABCG2 was blocked with the administration 
of FTC in the K562/ABCG2 cells treated with the respective drugs, a decrease in Bcr-Abl 
protein levels could be detected similarly to that observed in K562 cells. Protein levels of 
ABCG2 and targeted anti-cancer drugs                                                 Csilla Hegedüs, PhD thesis 
 47
the c-Abl kinase were comparable in each sample, also verifying uniform sample loading. 
Similar results were obtained when the Western blots were probed with the anti-c-Abl 
(24-11) antibody, which recognizes a protein region within the C-terminus of the c-Abl 
kinase (data not shown). 
 
 
Figure 11. Levels of Bcr-Abl and c-Abl kinases in Bcr-Abl inhibitor-treated K562 and 
K562/ABCG2 cells. 4*105/mL cells were treated with 500 nM imatinib, 25 nM nilotinib, 5 nM 
dasatinib or 50 nM bosutinib in the absence or in the presence of 5 µM FTC for 48 hours. Cell 
lysates were prepared and 40 µg protein extracts were probed by Western blot using the anti-c-
Abl (K-12) antibody. A representative image of two independent experiments is shown. 
 
Collectively, results of the cellular toxicity and Western blot experiments suggest that 
similarly to imatinib, ABCG2 can restrict the intracellular action of nilotinib and 
dasatinib as well, by preventing these compounds from reaching and inhibiting their 
intracellular target kinase Bcr-Abl. Contrarily, cellular toxicity and Bcr-Abl 
phosphorylation data obtained using bosutinib-treated K562 and K562/ABCG2 samples 
render it unlikely that ABCG2 transports bosutinib efficiently enough to reduce its 
intracellular concentration below the drug efficacy threshold. 
In order to investigate direct ABCG2-mediated transport of nilotinib, dasatinib and 
bosutinib, we attempted to set up an experimental system which would not require 
radioactively or fluorescently labeled drugs for detection. K562 and K562/ABCG2 cells 
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were incubated with the Bcr-Abl inhibitors at 37 °C for 60 minutes at the concentrations 
indicated in Fig.12. Cells were then washed and precipitated in acetonitrile containing 
imatinib as an internal standard. The intracellular amount of Bcr-Abl inhibitors was then 
determined by HPLC-MS by the laboratory of Zoltán Takáts as described in section 4.13. 
As shown in Fig. 12, we found that K562/ABCG2 cells accumulated significantly less 
nilotinib and dasatinib than the parental K562 cells, whereas only a very slight decrease 






In summary, we show that the Bcr-Abl kinase inhibitory effect of the second 
generation Bcr-Abl inhibitors nilotinib and dasatinib, but not that of bosutinib is 
restricted by ABCG2-mediated active efflux. 
 
5.1.6. Effect of nilotinib, dasatinib and bosutinib on the ATPase activity of 
ABCG2 
To gain further information about the interaction profile of ABCG2 and the 
investigated second generation Bcr-Abl inhibitors, we performed ABCG2 ATPase 
measurements using ABCG2-containing Sf9 membrane preparations. In these 
experiments, modulatory effect of the Bcr-Abl inhibitors on the ATPase activity of 
Figure 12. Intracellular accu-
mulation of nilotinib, dasatinib and 
bosutinib in K562/ABCG2 cells. 
4*105/mL K562 or K562/ABCG2 
cells were incubated with 25 nM 
nilotinib, 5 nM dasatinib or 10 nM 
bosutinib at 37 °C for 60 minutes. 
Following multiple washing steps, 
cells were precipitated with 
acetonitrile containing 30 nM 
imatinib as an internal standard. 
Intracellular amount of the 
investigated Bcr-Abl inhibitors were 
determined by HPLC-MS. Data 
obtained from K562/ABCG2 samples 
were plotted relative to the 
respective drug amounts measured in 
K562 cells (100%). Mean ± SE 
values of at least two independent 
experiments (each performed in 
duplicates) are shown.
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ABCG2 could be tested over significantly wider concentration ranges than those 
applicable in the K562 cellular toxicity measurements. As shown in Fig. 13, low 
nanomolar concentrations of nilotinib stimulated the high basal ATPase activity of the 
transporter, which corresponds to our previous findings demonstrating that nilotinib is a 
transported substrate of ABCG2. Nevertheless, a decreasing ABCG2 ATPase activity 
could be detected in the presence of higher, micromolar concentrations of nilotinib. In the 
case of dasatinib and bosutinib, we measured no ABCG2 ATPase modulatory effect 
under 1 µM concentrations of the drugs. When administered at 10-20 µM concentrations, 
however, both dasatinib and bosutinib decreased the basal ABCG2 ATPase, with 
bosutinib displaying a more pronounced effect. Altogether, these data imply that higher 
concentrations of the investigated Bcr-Abl inhibitors might have an ABCG2 inhibitory 
effect.    
 
5.1.7. Nilotinib, dasatinib and bosutinib inhibit ABCG2-mediated Hoechst 33342 
transport 
Inhibition of the function of ABCG2 by the investigated Bcr-Abl inhibitors which 
were suggested by the ATPase measurements (Fig. 13) might lead to re-senzitization of 
cells towards simultaneously administered ABCG2 substrate cytotoxic agents. To test 
this effect, we measured whether nilotinib, dasatinib or bosutinib could inhibit the 
Figure 13. Modulation 
of the ATPase activity of 
ABCG2 by nilotinib, 
dasatinib and bosutinib. 
Concentration-dependent 
effect of the investigated 
Bcr-Abl inhibitors on the 
basal ATPase activity of 
ABCG2 was measured 
using isolated cholesterol-
loaded Sf9 membranes 
containing ABCG2. Mean 
± SE values of at least 
three independent 
experiments (each 
performed in duplicates) 
are shown. 
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ABCG2-mediated transport of the Hoechst 33342 dye. Uptake of Hoechst 33342 was 
measured in K562/ABCG2 cells in the absence or in the presence of increasing 
concentrations of the Bcr-Abl inhibitors. ABCG2 inhibitory effect of the respective 
concentration of the Bcr-Abl inhibitors was plotted relative to the Hoechst 33342 uptake 
measured under maximal FTC-mediated inhibition of ABCG2 function. Similarly to 
imatinib (195), all of the investigated second generation Bcr-Abl inhibitors could inhibit 
the ABCG2-dependent Hoechst 33342 accumulation in a concentrations-dependent 
manner (Fig. 14). While nilotinib efficiently inhibited ABCG2-mediated Hoechst 33342 
uptake in a nanomolar concentration range, dasatinib and bosutinib displayed their 
inhibitory effect only when they were applied at higher than 1 µM concentration. 
Collectively, these results suggest that the investigated Bcr-Abl inhibitors might also 
inhibit the function of the ABCG2 transporter most probably through potential drug-drug 
interactions in its substrate binding pocket, which might result in chemo-sensitization and 








Figure 14. Inhibition of ABCG2-
mediated Hoechst 33342 transport by 
nilotinib, dasatinib and bosutinib. 
Concentration-dependent inhibitory 
potential of the investigated Bcr-Abl 
inhibitors on ABCG2-mediated Hoechst 
33342 transport was measured in intact 
K562/ABCG2 cells. Changes in 
fluorescence corresponding to the 
intracellular accumulation of Hoechst 
33342 were followed real-time using 
spectrofluorometry, in the absence of 
drugs (F0), in the presence of the 
respective Bcr-Abl inhibitor (Fx) and in 
the simultaneous presence of the Bcr-Abl 
inhibitor and 2 µM FTC (Fi). Data 
representing the inhibitory potential of the 
Bcr-Abl inhibitors relative to the 
maximum FTC-mediated inhibition were 
calculated as (Fx-F0)/(Fi-F0)*100. Mean ± 
SD values of three independent 
experiments are shown. 
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5.2. Interaction of ABCG2 and small molecule inhibitors of the 
EGFR/PI3K/Akt/mTOR cascade 
The aim of the second project presented in my thesis was to give detailed biochemical 
characterization of the interaction between the ABCG2 multidrug transporter and small 
molecule inhibitors of the Epidermal Growth Factor Receptor (EGFR) and the 
downstream PI3K/Akt/mTOR signaling cascade. 
 
 
Figure 15. The EGFR/PI3K/Akt/mTOR signaling cascade and its small molecule inhibitors 
investigated in this study. The Epidermal Growth Factor Receptor (EGFR) belongs to the ErbB 
family of receptor tyrosine kinases. Upon ligand binding followed by dimerization, the receptor is 
phosphorylated thus activating phosphatidylinositol 3-kinase (PI3K). PI3K generates 
phosphatidylinositol (3,4,5) trisphosphate (PIP3), which results in subsequent plasma membrane 
recruitment and phosphoinositide-dependent protein kinase-1 (PDK1)-mediated phosphorylation 
and activation of Akt kinase. Downstream targets of activated Akt include the mammalian target 
of rapamycin (mTOR) kinase, which can further phosphorylate p70S6 kinase. Small molecule 
inhibitors used in this study and their intracellular targets are indicated in the figure. PM: 
plasma membrane. 
 
 EGFR has been described to display uncontrolled kinase activity in various solid 
tumors, therefore it soon emerged as a promising molecular drug target in cancer 
therapies (181-183,191). Papers reporting on the interaction of gefitinib, the first applied 
small molecule inhibitor of EGFR, and ABCG2 were soon published (195,203-208). 
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With gefitinib used as a positive control, we aimed to investigate whether ABCG2 
interacted with the therapeutically relevant second generation EGFR inhibitors 
vandetanib, pelitinib and neratinib (Fig. 15, Table 4).  
EGFR signaling (76) and also the PI3K/Akt/mTOR signaling axis (78-84,233) have 
been implicated in the regulation of ABCG2, therefore in these studies we also included 
pharmacological inhibitors of the PI3K/Akt/mTOR cascade, namely wortmannin and 
LY294002 which are inhibitors of the PI3K, and rapamycin which is an inhibitor of the 
mTOR kinase. Schematic representation of the EGFR/PI3K/Akt/mTOR signaling 
pathway and the intracellular targets of the small molecule inhibitors investigated in this 
study are shown in Fig. 15. 
 
  Gefitinib Vandetanib Pelitinib Neratinib 
Aliases Iressa/ZD1839 Zactima/ZD6474 EKB-569 HKI-272 














Table 4. EGFR inhibitors investigated in this study. ASM: Advanced solid malignancies; 
CRC: Colorectal cancer; NSCLC: Non-small cell lung cancer. (Information on drugs is also 
available in the Drug Dictionary of the US National Cancer Institute.) 
 
5.2.1. Characterization of the membrane- and cell-based model systems applied 
For the biochemical characterization of the interaction between ABCG2 and the 
applied inhibitors of the EGFR/PI3K/Akt/mTOR signaling pathway, we employed both 
membrane- and cell-based model systems. Besides human wild-type ABCG2, in some 
experiments we also used the N-terminally GFP-tagged ABCG2 protein variant. GFP-
ABCG2 has earlier been reported to show similar subcellular localization and functional 
characteristics to the untagged ABCG2 protein species (211).  
Expression of the untagged or GFP-tagged ABCG2 protein in isolated Sf9 membrane 
fragments was tested by Western blot. As shown in Fig. 16A, both ABCG2 and GFP-
ABCG2 were correctly expressed in the insect membranes in their core glycosylated 
forms (41,211). Total and cell surface expression levels of ABCG2 in parental A431, 
A431/ABCG2, PLB/ABCG2 and MDCKII/GFP-ABCG2 were compared by Western 
blot and by labeling with 5D3 and subsequent flow cytometry analysis, respectively (Fig. 
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16B -C). Both ABCG2 and GFP-ABCG2 were expressed in a fully glycosylated form in 
the applied ABCG2 expressing mammalian cells (Fig. 16B) (41,211). Correct plasma 
membrane localization of the transporter in A431/ABCG2, PLB/ABCG2 and 
MDCKII/GFP-ABCG2 cells was confirmed by immunostaining with the 5D3 antibody 




Figure 16. ABCG2 and GFP-ABCG2 expression in the model systems used. Total ABCG2 
protein levels were probed by Western blot using the BXP-21 antibody in (A) isolated Sf9 
membranes containing (lane 1) ABCG2 or (lane 2) GFP-ABCG2;  and in (B) the mammalian cell 
lines (lane 1) A431, (lane 2) MDCKII/GFP-ABCG2, (lane 3) PLB/ABCG2 and (lane 4) 
A431/ABCG2. (C) Cell surface expression of ABCG2 in the applied cell lines was measured by 
indirect labeling with IgG2b (isotype control, IT) or 5D3 antibodies and Alexa-Fluor-647-
conjugated secondary antibodies, followed by flow cytometry analysis. Representative images of 
three independent experiments are shown. 
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In the case of MDCKII/GFP-ABCG2 cells, the 5D3 positive ABCG2-expressing cells 
also showed homogenous and strong GFP fluorescence indicating no cleavage of the GFP 
tag (data not shown).  No ABCG2 protein expression could be detected in parental A431 
cells (Fig. 16B-C). 
As shown in Fig. 16B-C, we found that expression levels of the ABCG2 protein varied 
between the applied ABCG2 expressing mammalian cell lines. These findings were 
confirmed in the Hoechst 33342 uptake experiments (Fig. 17), where A431/ABCG2 cells 
showed the highest Hoechst 33342 transport capacity. PLB/ABCG2 and MDCKII/GFP-
ABCG2 cells displayed lower but significant ABCG2-dependent Hoechst 33342 
transport capacity. In correlation with the ABCG2 expression data (Fig. 16B-C), no 




5.2.2. Effect of the investigated EGFR inhibitors on the ATPase activity of 
ABCG2 
In order to screen the potential interaction between the investigated inhibitors of 
EGFR and ABCG2, we measured the concentration-dependent modulatory effect of the 
drugs on the ABCG2 ATPase activity. In these experiments, cholesterol-loaded Sf9 
membrane fragments containing ABCG2 were used. As shown in Fig. 18A, pelitinib 
strongly stimulated the basal ATPase activity of ABCG2, similarly to gefitinib which is 
Figure 17. ABCG2 function in 
the model cell lines applied. 
Specific ABCG2 function in the 
indicated model cells was followed 
by real-time spectrofluorometric 
detection of the cellular 
accumulation of the ABCG2 
substrate dye, Hoechst 33342. 
Representative images of at least 
three independent measurements 
are shown. 
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known to be transported by ABCG2 (203,204,207,208). In contrast, we measured 
concentration-dependent decrease in the basal ATPase activity of ABCG2 by neratinib, 
which at higher than 5 µM doses, inhibited the ABCG2 ATPase to a similar extent as the 
specific ABCG2 inhibitor Ko143 (data not shown). Vandetanib displayed a slight 
inhibitory effect on the basal ATPase activity of ABCG2 (Fig. 18A). 
We also tested whether the investigated EGFR inhibitors could affect the stimulated 
ATPase activity of ABCG2. In this experimental setup, we expected that compounds 
which interact with the transporter could decrease the quercetin-stimulated ABCG2 
ATPase (127,222,223). We found that each EGFR inhibitor, when applied at micromolar 
concentrations, could inhibit the stimulated ATPase activity of ABCG2, with neratinib 
displaying the most pronounced effect (Fig. 18B). Altogether, these data suggest a 





Figure 18. Modulation of the ATPase activity of ABCG2 by the investigated EGFR 
inhibitors. Concentration-dependent effect of the investigated EGFR inhibitors on the (A) basal 
and the (B) stimulated (with 1 µM quercetin) ATPase activity of ABCG2 were measured using 
isolated cholesterol-loaded Sf9 membranes containing ABCG2. Data were normalized to the 
ABCG2 ATPase activities measured in the absence of EGFR inhibitors. Mean ± SE values of at 
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5.2.3. ABCG2 confers resistance to gefitinib and pelitinib, whereas intracellular 
action of vandetanib and neratinib is not restricted by the transporter 
As a next step, we aimed to study whether the presence of ABCG2 could modify the 
action of the EGFR inhibitors in a cellular milieu. To this end, we measured the cellular 
toxicity of the drugs in A431 and A431/ABCG2 cells. A431 epidermoid carcinoma cells 
overexpress EGFR, rely on active EGFR signaling for survival and therefore show 
sensitivity to inhibition of the receptor (203). Cells were treated with increasing 
concentrations of the drugs for 72 hours in the absence or the presence of 5 µM FTC. 
Cellular viability was determined with the MTT assay (see section 4.9). IC50 values 
calculated from the respective killing curves are shown in Table 5.  
 
Cellular IC50  
(nM; mean ± SE)  
Gefitinib Vandetanib Pelitinib Neratinib 
A431 parental 106.1 ± 7.5 913.5 ± 61.3 23.2 ± 5.2 12.1 ± 2.2 
-FTC 
A431/ABCG2 197.7 ± 13.1 979.2 ± 79.2 133.2 ± 21.9 21.8 ± 5.4 
A431 parental 81.4 ± 7.4 n.d. 26.3 ± 3.2 11.7 ± 1.3 
+FTC 
A431/ABCG2 82.0 ± 1.6 n.d. 27.0 ± 4.8 22.7 ± 1.3 
 
Table 5. Cellular toxicity of EGFR inhibitors in EGFR-overexpressing A431 and 
A431/ABCG2 cells. 
 
 As compared to parental A431 cells, we measured increased IC50 values for gefitinib 
and pelitinib in A431/ABCG2 cells. This decreased sensitivity of A431/ABCG2 cells 
towards gefitinib and pelitinib could be fully reversed by the specific blockade of 
ABCG2 function with FTC. Neratinib also showed slightly decreased cellular toxicity in 
A431/ABCG2 cells; however, this phenomenon was unaffected by the presence of the 
specific ABCG2 inhibitor FTC. A431 and A431/ABCG2 cells were similarly sensitive to 
vandetanib. These results imply that similarly to gefitinib, ABCG2 can confer cellular 
resistance to pelitinib, whereas cellular toxicity of neratinib and vandetanib is not 
restricted by the transporter. 
To further investigate drug effects on a molecular level, we followed the 
phosphorylation status of EGFR in A431 and A431/ABCG2 cells treated with increasing 
concentrations of the applied EGFR inhibitors (Fig. 19). Serum-starved A431 or 
A431/ABCG2 cells were stimulated with hEGF for 15 minutes and then were exposed to 
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the indicated concentrations of EGFR inhibitors for additional 15 minutes. Cellular 
proteins were extracted as described in section 4.11, and phosphorylation of EGFR at 
Tyr1068 was probed by Western blot.  
 
Figure 19. Phosphorylation of EGFR in EGFR inhibitor-treated A431 and A431/ABCG2 
cells. 7.5*105/mL cells were seeded in serum-free medium. After 16 hours, cells were stimulated 
with 20 ng/mL hEGF for 15 minutes then were exposed to the EGFR inhibitors (A) gefitinib, (B) 
pelitinib, (C) neratinib or (D) vandetanib at the indicated concentrations for additional 15 
minutes. Cell lysates were prepared and 20 μg protein extracts were probed for phosphorylation 
of EGFR at Tyr1068 by Western blot. Beta-actin was stained to check sample loading. 
Representative blots of three independent experiments are shown. 
 
As shown in Fig. 19, stimulation with hEGF resulted in strong phosphorylation of 
EGFR in both A431 and A431/ABCG2 cells. Consistently with the results obtained in the 
cellular toxicity measurements, we detected significantly higher levels of phosphorylated 
EGFR in A431/ABCG2 cells treated with gefitinib (Fig. 19A) or pelitinib (Fig. 19B) as 
compared to those measured in parental A431 cells. These findings strongly suggest that 
the presence of ABCG2 restrict the intracellular kinase inhibitory action of these drugs 
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most probably by active efflux. In the case of neratinib (Fig. 19C) or vandetanib (Fig. 
19D) treatment, we measured similar levels of phosphorylated EGFR in A431 and 
A431/ABCG2 cells, further implying that the cytotoxic effect of these drugs is not 
modified by the presence of ABCG2. 
 
5.2.4. The investigated EGFR inhibitors block ABCG2 function and enhance the 
cellular accumulation of ABCG2 substrates 
In the next series of experiments, we studied whether the EGFR inhibitors used in this 
study could block the function of ABCG2, which could result in re-sensitization of cells 
resistant to simultaneously administered ABCG2 substrate drugs. It has been shown 
previously that conformational changes of ABCG2 can be monitored with the anti-
ABCG2 5D3 antibody (70,215). ABCG2 has at least two distinct conformations exposing 
the extracellular 5D3 epitope displaying low or high affinity towards the antibody. The 
highly 5D3 immunoreactive form of ABCG2 corresponds to the PFA-fixed or the Ko143- 
or FTC-inhibited protein conformation (215). Therefore, drug-mediated increase in the 
5D3 binding affinity of the transporter can be exploited to screen for compounds bearing 
ABCG2 inhibitory potential (223). 
 
  Gefitinib Vandetanib Pelitinib Neratinib 
5D3 binding in A431/ABCG2 cells 
(% relative to Ko143; mean ± SD) 
71.3 ± 12.7 9.3 ± 0.3 41.9 ± 6.5 26.0 ± 0.7 
EC50 of inhibition of Hst 33342 
efflux in PLB/ABCG2 cells       
(µM; mean ± SD) 
0.6 ± 0.1 5.9 ± 0.5 0.9 ± 0.0 0.9 ± 0.0 
 
Table 6. Effect of the investigated EGFR inhibitors on the 5D3 binding and Hoechst 33342 
transport capacity of ABCG2. 
 
Changes in the 5D3 binding capacity of ABCG2 in the presence of increasing 
concentrations of EGFR inhibitors was tested by flow cytometry in A431/ABCG2, 
PLB/ABCG2 and MDCKII/GFP-ABCG2 cells as described in section 4.7. The most 
pronounced effect was measured in the presence of 10 µM EGFR inhibitors. Statistical 
analysis of the data obtained using A431/ABCG2 cells and 10 µM EGFR inhibitors are 
summarized in Table 6. Geometric mean values of the histograms representing 5D3-
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labeled cells were corrected with those representing isotype control (IgG2b) labeled cells 
of the corresponding treatment. Data were calculated as the percentage of the maximal 
5D3 binding obtained in the presence of 1 µM Ko143. All of the investigated EGFR 
inhibitors provoked increased 5D3 binding of ABCG2 with gefitinib and pelitinib 
displaying the most pronounced effect in all of the investigated cell types. These findings 
indicate that the investigated EGFR inhibitors might efficiently block the function of the 
ABCG2 transporter. Therefore, as a next step, we studied the inhibitory potential of the 
EGFR inhibitors applied on the ABCG2-mediated transport of Hoechst 33342 in 
A431/ABCG2 and PLB/ABCG2 cells, and on the transport of mitoxantrone in 
A431/ABCG2 cells. All of the investigated EGFR inhibitors efficiently inhibited Hoechst 
33342 transport in PLB/ABCG2 cells (Table 6) and A431/ABCG2 cells (data not shown) 
in a concentration-dependent manner. Furthermore, we found that 10 µM of gefitinib, 
pelitinib or neratinib completely blocked the ABCG2-mediated efflux of mitoxantrone 
from A431/ABCG2 cells (Fig. 20).Vandetanib at 10 µM concentration could also slightly 
inhibit mitoxantrone transport in A431/ABCG2 cells; however, to a lesser extent than the 
other EGFR inhibitors applied (Fig. 20). Collectively, these data suggest that gefitinib, 
pelitinib, neratinib and vandetanib might reverse ABCG2-associated drug resistance by 
inhibiting the function of the transporter. 
 
 
Figure 20. Inhibition of ABCG2-
mediated mitoxantrone (MX) efflux 
by the investigated EGFR inhibitors. 
2*105 A431/ABCG2 cells were 
incubated with 5 μM MX (dotted line), 
5 μM MX with 10 μM of EGFR 
inhibitors (solid line) or 5 μM MX with 
10 μM of EGFR inhibitors and 1 μM 
Ko143 (solid, bold line) at 37 °C for 
30 minutes. Cellular fluorescence of 
MX in live cells was determined by 
flow cytometry. Representative 
histograms of three independent 
experiments are shown. 
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5.2.5. Gefitinib exposure enhances ABCG2 protein expression and causes cellular 
resistance to mitoxantrone 
In the next set of experiments, we aimed to investigate whether the exposure of cancer 
cells to the EGFR inhibitor gefitinib influences the expression of ABCG2. To this end, 
we analyzed ABCG2 protein expression and function in gefitinib-resistant NCI-H1650 
cells. NCI-H1650 cells were exposed to gefitinib for 72 hours and the surviving gefitinib-
resistant subclones (C11, G7, O11, P8 and P11, nomenclature of Kwak et al (214)) were 
isolated and characterized previously by Kwak et al (214). 
First, we measured cell surface expression of ABCG2 in the parental NCI-H1650 cells 
and the C11, G7, O11, P8 and P11 gefitinib-resistant subclones by 5D3 labeling. We 
found detectable endogenous expression of the transporter in parental NCI-H1650 cells, 
and C11, G7 and P11 gefitinib resistant clones showed elevated plasma membrane 
protein levels of ABCG2 (data not shown). As clone G7 showed the highest increase in 
5D3 binding as compared to parental NCI-H1650 cells, in the further measurements we 
analyzed expression and function of the ABCG2 protein in these cells. 
Levels of the ABCG2 protein in NCI-H1650 and NCI-H1650 G7 cells were compared 
by Western blot. As shown in Fig. 21A, endogenous ABCG2 could be detected in 
parental NCI-H1650 cells by Western blot, and NCI-H1650 G7 cells showed an increase 
in total ABCG2 protein levels. Elevated levels of the transporter in the plasma membrane 
of NCI-H1650 G7 cells were further confirmed by 5D3 labeling and confocal microscopy 
measurements (Fig. 21B). 
Next, we tested the function of ABCG2 in parental NCI-H1650 and the gefitinib-
resistant NCI-H1650 G7 cells. Intracellular accumulation of mitoxantrone was measured 
in the absence and in the presence Ko143 by flow cytometry. As shown in Fig. 21C, in 
the absence of Ko143, NCI-H1650 G7 cells could accumulate less mitoxantrone than the 
parental NCI-H1650 cells, whereas administration of Ko143 enhanced mitoxantrone 
uptake in both cell types. Long-term consequences of enhanced expression of the 
ABCG2 protein in NCI-H1650 G7 cells were followed by measuring the cellular toxicity 
of mitoxantrone. NCI-H1650 and NCI-H1650 G7 cells were exposed to mitoxantrone in 
the absence or in the presence of Ko143 for 72 hours, and cellular viability was 
determined by the MTT assay. NCI-H1650 G7 cells showed increased resistance towards 
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mitoxantrone as compared to NCI-H1650 cells, and co-incubation with Ko143 restored 
mitoxantrone sensitivity of both cell types (Fig. 21D). 
 
 
Figure 21. Enhanced expression and function of ABCG2 in gefitinib-resistant NCI-H1650 
cells. (A) Total ABCG2 protein levels in NCI-H1650 and gefitinib-resistant NCI-H1650 G7 cells 
were determined by Western blot using 50 μg cellular protein extracts and the BXP-21 antibody. 
A representative blot of three independent experiments is shown. (B) Cell surface expression of 
ABCG2 was measured by confocal microscopy using the 5D3 antibody. A representative image of 
two independent experiments is shown. (C) 2*105 cells were incubated with 2 μM mitoxantrone in 
the absence or presence of 1 μM Ko143 at 37 °C for 30 minutes. Cellular fluorescence of 
mitoxantrone in live cells was determined by flow cytometry. A representative histogram of eight 
independent measurements is shown. (D) 4*103 NCI-H1650 or NCI-H1650 G7 cells were 
exposed to mitoxantrone in the absence or the presence of 1 μM Ko143 for 72 hours. Cellular 
viability was determined by the MTT assay. Mean ± SE values of three independent experiments 
(each performed in quadruplicates) are shown. 
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5.2.6. Effect of the investigated pharmacological PI3K/Akt/mTOR inhibitors on 
the ATPase activity of ABCG2 
The PI3K/Akt/mTOR signaling cascade, which is downstream of activated EGFR 
(Fig. 15), has been implicated in the regulation of the ABCG2 transporter. Inhibition of 
Akt signaling was reported to provoke rapid translocation of ABCG2 from the plasma 
membrane to intracellular compartments in several cell types (79-84), a phenomenon 
which has also been associated with attenuated ABCG2 function (79,81,83,84) and 
subsequent reversal of drug resistance caused by the transporter (83,84). Nevertheless, 
opposing data regarding the involvement of the PI3K/Akt axis and the downstream 
mTOR kinase in the regulation of the plasma membrane localization of ABCG2 has also 
been published (78,81). In our study, we also intended to address whether 
PI3K/Akt/mTOR signaling was involved in the rapid regulation of the plasma membrane 
localization of ABCG2 in our available model systems. In the above referenced reports, 
wortmannin, LY294002 and rapamycin were applied for the pharmacological inhibition 
of the PI3K and mTOR kinases, respectively (Fig. 15), to manipulate cellular signal 
transduction. Given the multispecific drug recognition capability of ABCG2, however, as 
a first step, we tested whether these compounds directly interacted with the transporter. 
 
Figure 22. Modulation of the ATPase activity of ABCG2 by the investigated 
pharmacological PI3K/Akt/mTOR inhibitors. Concentration-dependent effect of the investigated 
PI3K/Akt/mTOR inhibitors on the (A) basal and the (B) stimulated (with 1 µM quercetin) ATPase 
activity of ABCG2 were measured using isolated cholesterol-loaded Sf9 membranes containing 
ABCG2. Data were normalized to the ABCG2 ATPase activities measured in the absence of 
PI3K/Akt/mTOR inhibitors. Mean ± SE values of at least three independent experiments (each 
performed in duplicates) are shown 
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Modulation of the basal (Fig. 22A) and the stimulated (Fig. 22B) ATPase activity of 
ABCG2 by increasing concentrations of wortmannin, LY294002 and rapamycin were 
measured in Sf9 membranes containing ABCG2. At its experimentally relevant 10 µM 
concentration, LY294002 slightly stimulated the basal ABCG2 ATPase, whereas the 
other PI3K inhibitor wortmannin showed no modulatory effect at all (Fig. 22A). The 
mTOR kinase inhibitor rapamycin decreased the basal ATPase activity of the transporter 
in a concentration-dependent manner and produced a pronounced inhibition when applied 
at 10 µM concentration (Fig. 22A). Accordingly, marked inhibition of the quercetin-
stimulated ABCG2 ATPase activity could be measured only in the case of 10 µM 
rapamycin (Fig. 22B). In contrast, 10 µM LY294002 displayed only a slight inhibitory 
effect, whereas wortmannin showed no effect on the quercetin-stimulated ATPase 
activity of the transporter (Fig. 22B). As GFP-ABCG2 was also used in some 
experiments, we also tested the effect of the investigated drugs on the basal (Fig. 23A) 
and the stimulated (Fig. 23B) ATPase activity of GFP-ABCG2. In these measurements, 
similar ATPase modulatory patterns by the investigated compounds were detected to 
those obtained in the case of the untagged ABCG2 protein variant (Fig. 22). 
 
Figure 23. Modulation of the ATPase activity of GFP-ABCG2 by the investigated 
pharmacological PI3K/Akt/mTOR inhibitors. Concentration-dependent effect of the investigated 
PI3K/Akt/mTOR inhibitors on the (A) basal and the (B) stimulated (with 1 µM quercetin) ATPase 
activity of GFP-ABCG2 were measured using isolated cholesterol-loaded Sf9 membranes 
containing GFP-ABCG2. Data were normalized to the GFP-ABCG2 ATPase activities measured 
in the absence of PI3K/Akt/mTOR inhibitors. Mean ± SE values of at least three independent 
experiments (each performed in duplicates) are shown. 
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Collectively, these data suggest that in contrast to wortmannin, LY294002 and 
rapamycin interact with ABCG2. Nevertheless, both stimulation and inhibition of the 
basal ABCG2 ATPase activity by substrates transported at higher or lower rates, 
respectively has been described (41). Moreover, some compounds which interact with the 
transporter do not modulate the ABCG2 ATPase activity at all (127,222). Therefore, 
based on these results we could not determine the nature of the interaction between 
ABCG2 and rapamycin, and could not exclude a potential interaction of wortmannin with 
ABCG2 either. Also, it remained to be determined whether the potential interaction 
between the transporter and LY294002, which only slightly influenced the ABCG2 
ATPase or rapamycin is also relevant in a cellular context. 
 
5.2.7. The presence of ABCG2 does not influence target kinase inhibition by the 
investigated PI3K/Akt/mTOR inhibitors 
As a next step, we aimed to determine whether the presence of ABCG2 could restrict 
the intracellular action of the applied PI3K/Akt/mTOR inhibitors at their relevant target 
kinase sites (Fig. 15), which would suggest active ABCG2-mediated transport of the 
drugs. Stimulation of EGFR-overexpressing A431 cells with hEGF results in activation 
of the downstream PI3K/Akt signaling cascade (203,234); therefore, we investigated Akt 
and p70S6 kinase phosphorylation patterns in hEGF-stimulated A431 and A431/ABCG2 
cells treated with wortmannin, LY294002 or rapamycin. Drugs were used at their 
experimentally relevant concentrations (235), as indicated in Fig. 24. In addition, the 
effect of 10 µM rapamycin was also tested, since it showed inhibition of the ATPase 
activity of ABCG2 at this concentration. Phosphorylation of the Akt kinase and p70S6 
kinase were probed by Western blot using antibodies which react with Akt when it is 
phosphorylated at Ser473 or p70S6 kinase when it is phosphorylated at Thr389. As 
expected, hEGF treatment resulted in enhanced phosphorylation of both Akt and p70S6 
kinases in A431 and A431/ABCG2 cells (Fig. 24A-B). Phosphorylation of Akt in hEGF-
treated A431 cells could be fully prevented by wortmannin treatment, and we also 
detected decreased levels of phosphorylated Akt in hEGF-treated A431 cells exposed to 
LY294002 (Fig. 24A). Phosphorylation of the downstream p70S6 kinase was also 
attenuated in hEGF-stimulated A431 cells exposed to wortmannin or LY294002, whereas 
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it could be fully abolished by exposure to rapamycin (Fig. 24B). Phosphorylation patterns 
of Akt and p70S6 kinases were similar in A431/ABCG2 cells exposed to the respective 
drug treatments to those measured in A431 cells (Fig. 24A-B), suggesting that the 
intracellular efficiencies of wortmannin, LY294002 or rapamycin are unaltered by the 
presence of ABCG2. These findings render it unlikely that any of these compounds, 
when applied at the experimentally relevant drug concentrations, is transported by 





Figure 24. Effect of the investigated pharmacological PI3K/Akt/mTOR inhibitors on the 
phosphorylation of Akt or p70S6 kinases in A431 and A431/ABCG2 cells. 7.5*105/mL cells 
were seeded in serum-free medium. After 16 hours, cells were stimulated with 20 ng/mL hEGF 
for 15 minutes then were exposed to wortmannin, LY294002 or rapamycin at the indicated 
concentrations for additional 15 minutes. Cell lysates were prepared and 20 μg protein extracts 
were probed for phosphorylation of (A) Akt kinase at Ser473 and (B) p70S6 kinase at Thr389 by 
Western blot. Beta-actin was stained to check sample loading. Representative blots of three 
independent experiments are shown. 
 
5.2.8. LY294002 and rapamycin directly inhibit ABCG2 function 
Next, we investigated whether wortmannin, LY294002 or rapamycin could inhibit the 
function of the ABCG2 transporter. To this end, we tested if the presence of the 
investigated inhibitors could generate a conformational change in the ABCG2 protein 
similarly to Ko143, which thereby would increase the 5D3 binding affinity of the 
transporter (215,223). 5D3 binding of various cell lines overexpressing ABCG2 was 
measured in the presence of increasing concentrations of wortmannin, LY294002 or 
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rapamycin. Geometric mean values of the histograms representing specific 5D3 binding 
were corrected with those obtained in cells labeled with isotype control antibodies in the 
presence of the respective drug. None of the investigated compounds provoked a 
remarkable increase in 5D3 binding of the ABCG2 expressing cells at 0.1 µM or 1 µM 
concentrations (data not shown). Wortmannin did not affect the 5D3 binding affinity of 
ABCG2 at 10 µM concentration either (Table 7). In contrast, both LY294002 and 
rapamycin, when applied at 10 µM concentration, highly increased the 5D3 binding of 
ABCG2 in A431/ABCG2 cells (Table 7), and also in MDCKII/GFP-ABCG2 and 
PLB/ABCG2 cells (data not shown). These results imply that in contrast to wortmannin, 
LY294002 and rapamycin might efficiently inhibit the function of the ABCG2 
transporter. 
 
 Wortmannin LY294002 Rapamycin 
Aliases - - Sirolimus 
Target PI3K PI3K mTOR 
5D3 binding in A431/ABCG2 cells 
(% relative to Ko143; mean ± SD) 
no effect 63.2 ± 4.2 61.9 ± 10.6 
EC50 of inhibition of Hst 33342 
efflux in PLB/ABCG2 cells 
(μM; mean ± SD) 
no effect 11.2 ± 2.0 1.6 ± 0.2 
 
Table 7. Modulation of the 5D3 binding and Hoechst 33342 efflux capacity of ABCG2 by 
the investigated pharmacological PI3K/Akt/mTOR inhibitors. 
 
Therefore, next we studied whether the investigated PI3K/Akt/mTOR inhibitors could 
inhibit the transport of Hoechst 33342 and mitoxantrone, both of which are substrates of 
ABCG2. As shown in Table 7, in correlation with the 5D3 binding data, wortmannin had 
no effect on the Hoechst 33342 transport capacity of PLB/ABCG2 cells; whereas 
LY294002 and rapamycin inhibited Hoechst 33342 efflux from PLB/ABCG2 cells in a 
concentration-dependent manner. Similar results were obtained using A431/ABCG2 cells 
(data not shown). Similarly, 10 µM LY294002 and 10 µM rapamycin completely 
abrogated the efflux of mitoxantrone from A431/ABCG2 cells (Fig. 25A). In contrast, 
wortmannin showed no inhibitory effect on mitoxantrone transport in A431/ABCG2 
cells, even when applied at a 100-fold excess to its experimentally used 0.1 µM 
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concentration (Fig. 25A). Collectively, these results suggest that LY294002 and 
rapamycin directly inhibit the function of ABCG2, while wortmannin does not interact 




Figure 25. Inhibition of ABCG2-mediated mitoxantrone (MX) efflux and restoration of 
MX-sensitivity by the investigated pharmacological PI3K/Akt/mTOR inhibitors. (A) 2*105 
A431/ABCG2 cells were incubated with 5 μM MX (dotted line), 5 μM MX with PI3K/Akt/mTOR 
inhibitors at the indicated concentrations (solid line) or 5 μM MX with inhibitors and 1 μM 
Ko143 (solid, bold line) at 37 °C for 30 minutes. Cellular fluorescence of MX in live cells was 
determined by flow cytometry. Representative histograms of three independent experiments are 
shown. (B) 4*103 A431 or A431/ABCG2 cells were treated with 5 μM FTC, 10 μM wortmannin, 
10 μM LY294002, 10 μM rapamycin or 50 nM MX either as a single agent or in combination for 
72 hours. Cellular viability was assessed by the MTT assay. Mean ± SE values of three 
independent experiments (each performed in quadruplicates) are shown. 
 
In order to reveal whether inhibition of ABCG2 function by LY294002 or rapamycin 
also results in the reversal of drug resistance caused by the transporter, we measured the 
cellular toxicity of mitoxantrone in A431 and A431/ABCG2 cells in the presence of the 
drugs indicated in Fig. 25B. Cells were exposed to the indicated treatments for 72 hours, 
and cellular viability was determined by the MTT assay. Treatment with wortmannin, 
LY294002 or rapamycin reduced the viability of both A431 and A431/ABCG2 cells. As 
we expected, A431/ABCG2 cells were resistant to mitoxantrone, and this resistance 
could be similarly reversed by administration of the specific ABCG2 inhibitor FTC, and 
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also by LY294002 and rapamycin. Re-sensitization of mitoxantrone-resistant 
A431/ABCG2 cells by LY294002 or rapamycin suggests that these compounds are 
indeed capable of long-term functional inhibition of the transporter thereby reversing 
multidrug resistance. In contrast, mitoxantrone resistance of A431/ABCG2 cells was 
unaffected by wortmannin, confirming results of the 5D3 binding (Table 7) and dye 
uptake (Table 7, Fig. 25A) experiments showing that wortmannin could not inhibit the 
function of ABCG2. Notably, cellular viability in the case of wortmannin, LY294002 and 
rapamycin treatment was similar in both A431 and A431/ABCG2 samples, further 
supporting that ABCG2 is not capable of hindering intracellular action of these 
PI3K/Akt/mTOR inhibitors by active efflux at the applied drug concentrations. 
Moreover, as wortmannin and LY294002, which both inhibit PI3K thereby preventing 
phosphorylation of Akt and the downstream p70S6 kinase (Fig. 24), produced distinct 
effects on reversing ABCG2-mediated mitoxantrone resistance (Fig. 25B), we concluded 
that the observed effects correlated with direct inhibition of ABCG2 function rather than 
with alterations in PI3K/Akt/mTOR signaling and subsequent potential changes in 
functional ABCG2 protein levels. 
 
5.2.9. Pharmacological inhibition of the EGFR/PI3K/Akt/mTOR cascade does not 
result in rapid internalization of ABCG2 
Inhibition of Akt signaling was shown to induce rapid translocation of ABCG2 from 
the plasma membrane to intracellular compartments in various cell types (79-84). This 
phenomenon has also been associated with attenuated ABCG2 transporter function 
(79,81,83,84) and subsequent reversal of ABCG2-mediated drug resistance (83,84). 
Nevertheless, opposing data has also been published showing that inhibition of PI3K/Akt 
signaling in human leukemia cells down-regulated overall ABCG2 protein levels rather 
than affecting only its plasma membrane localization (78). Involvement of the 
downstream mTOR kinase in the regulation of the plasma membrane insertion of ABCG2 
has also been controversial (81,233). Employing cell lines with either endogenous or 
forced ABCG2 or GFP-ABCG2 protein expression, in the current study we also 
addressed the issue concerning involvement of the PI3K/Akt/mTOR signaling axis in the 
regulation of ABCG2. 
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As a first approach, we used the anti-ABCG2 5D3 antibody to monitor cell surface 
transporter level in cells treated with pharmacological inhibitors of the PI3K/Akt 
signaling cascade. 5D3 is a conformation sensitive antibody which reacts with an epitope 
located in the third extracellular loop of ABCG2 (70,71,215). Fixation with PFA or 
incubation with FTC or Ko143 has been shown to induce a protein conformation of 




Figure 26. Detection of the appearance of an ABCG2-negative cell population in 
paraformaldehyde (PFA)-fixed cells with the conformation-sensitive anti-ABCG2 5D3 
antibody. 2.5*105 parental or GFP-ABCG2-expressing MDCKII cells or the mixture of the two 
cell types at the indicated ratios were fixed with PFA and were labeled with IgG2b (isotype 
control, IT) or 5D3 primary antibodies and Alexa-Fluor-647-conjugated secondary antibodies. 
Samples were analyzed by flow cytometry. Representative histograms of two independent 
experiments are shown. 
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In the experiments aiming to elucidate the role of PI3K/Akt signaling in the plasma 
membrane localization of ABCG2, we planned to use PFA-fixed cells. Therefore in the 
first control measurements we wanted to prove that 5D3 labeling quantitatively correlates 
with the amount of ABCG2 in the cell surface under PFA-fixed conditions and that it is 
also applicable to co-detect PFA-fixed cell populations showing decreased or abolished 
plasma membrane ABCG2 levels together with those showing maximum 5D3 binding. 
Parental and GFP-ABCG2 overexpressing MDCKII cells (Fig. 16B-C) were mixed in 
different ratios then were fixed with PFA and were subsequently stained with 5D3. As 
5D3 signals corresponded with the GFP-fluorescence intensities of the respective cell 
populations, we concluded that 5D3 labeling allows for sensitive and quantitative 
detection of plasma membrane ABCG2 levels in PFA-fixed cells (Fig. 26). 
 
Figure 27. Detection and functional consequences of decreased plasma membrane ABCG2 
levels. (A) Total ABCG2 protein levels of K562/ABCG2 cells stably expressing high 
(K562/ABCG2-H) or low (K562/ABCG2-L) amounts of the transporter were evaluated by 
Western blot using the BXP-21 antibody. Beta-actin was stained to check sample loading. A 
representative blot of three independent experiments is shown. (B) Cell surface expression of 
ABCG2 in K562/ABCG2-L or K562/ABCG2-H cells were measured by fixation with 
paraformaldehyde and labeling with IgG2b (isotype control, IT) or 5D3 primary antibodies and 
Alexa-Fluor-647-conjugated secondary antibodies. Samples were analyzed by flow cytometry. A 
representative histogram of two independent experiments is shown. (C) Specific ABCG2 function 
in K562/ABCG2-L or K562/ABCG2-H cells was followed by real-time spectrofluorometric 
detection of the cellular accumulation of the ABCG2 substrate dye, Hoechst 33342. A 
representative image of at least three independent measurements is shown. 
 




Figure 28.  Localization of ABCG2 in wortmannin-treated NCI-H1650, A431/ABCG2 and 
MDCKII/GFP-ABCG2 cells. Cells were treated with 100 nM wortmannin for 90 minutes at 37 
°C. (A) Phosphorylation of Akt at Ser473 was probed by Western blot. Beta-actin was stained to 
check sample loading. Representative blots of two independent experiments are shown. (B) 
2.5*105 untreated control and wortmannin-treated cells were fixed with paraformaldehyde 
(PFA), and were labeled with 5D3 or IgG2b primary antibodies and Alexa-Fluor-647-conjugated 
secondary antibodies. Samples were analyzed by flow cytometry. Geometric mean values of the 
histograms representing 5D3-labeled cells were corrected with those of IgG2b-labeled cells, and 
data were plotted as the percentage of 5D3 binding measured in untreated cells (100%). Mean ± 
SD values of three independent experiments are shown. (C) Control and wortmannin-treated 
polarized MDCKII/GFP-ABCG2 cells were fixed with PFA and were stained with the apical 
marker Alexa-Fluor-633-conjugated WGA and the nuclear stain DAPI. Subcellular distribution 
of GFP-ABCG2 was evaluated by confocal microscopy. Representative images of three 
independent experiments are shown. 
 
Next, K562 cells stably expressing high (K562/ABCG2-H) or low (K562/ABCG2-L) 
amounts of ABCG2 (Fig. 27A) were fixed with PFA and then were labeled with 5D3. 
Flow cytometry analysis of the K562/ABCG2-H and K562/ABCG2-L samples again 
revealed that 5D3 labeling of PFA-fixed cells quantitatively reflected the amount of the 
ABCG2 transporter in the plasma membrane (Fig. 27B). Notably, K562/ABCG2-L cells 
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which showed approximately one order of magnitude decrease in cell surface ABCG2 
levels as compared to K562/ABCG2-H cells still showed remarkable ABCG2-mediated 
Hoechst 33342 transport capacity (Fig. 27C). 
 
 
In order to investigate whether PI3K/Akt/mTOR signaling is involved in the rapid 
regulation of the plasma membrane localization of ABCG2, NCI-H1650 cells showing 
endogenous ABCG2 expression (Fig. 21A-B), or A431/ABCG2 cells engineered to 
overexpress ABCG2 and MDCKII/GFP-ABCG2 (Fig. 16B-C) were exposed to the PI3K 
inhibitor wortmannin for 90 minutes at 37 °C. Wortmannin was used because it does not 
Figure 29. Subcellular distribution of 
GFP-ABCG2 in rapamycin-treated 
polarized MDCKII/GFP-ABCG2 cells. 
Polarized MDCKII/GFP-ABCG2 cells 
were untreated or treated with 10 nM 
or 10 µM rapamycin for 90 minutes at 
37 °C. Cells were fixed with 
paraformaldehyde and were stained 
with the apical marker Alexa-Fluor-
633-conjugated WGA and the nuclear 
stain DAPI. Subcellular distribution of 
GFP-ABCG2 was evaluated by 
confocal microscopy. Representative 
images of three independent 
experiments are shown. 
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interact with ABCG2; therefore, PI3K/Akt signaling could be manipulated without direct 
functional modulation of the transporter. Under these conditions, wortmannin could 
efficiently prevent phosphorylation of Akt (Fig. 28A). Cells were fixed with PFA, and 
were then labeled with 5D3. As shown in Fig. 28B, wortmannin treatment did not 
significantly decrease 5D3 binding, therefore cell surface expression of ABCG2 in any of 
the cell lines tested, as compared to the untreated cells (100 %). In addition, treatment 
with either 10 µM LY294002 or 1 µM Ko143 for 90 minutes at 37 °C did not reduce the 
5D3 binding capacity and the corresponding cell surface levels of ABCG2 in any of the 
cell lines applied (data not shown). Moreover, we did not find any rapid effect of the 
investigated EGFR inhibitors on the plasma membrane insertion of ABCG2 either (data 
not shown). 
As a second approach, subcellular distribution of GFP-ABCG2 was followed in 
polarized MDCKII/GFP-ABCG2 cells by confocal microscopy (Fig. 28C). GFP-ABCG2 
co-localized with the apical marker WGA in untreated cells. Major apical localization 
and subcellular distribution of GFP-ABCG2 was not altered by wortmannin treatment. 
Brief exposure of MDCKII/GFP-ABCG2 cells to the downstream mTOR inhibitor 
rapamycin applied at the experimentally relevant 10 nM concentration (which does not 
inhibit ABCG2) or 10 µM concentration (which inhibits ABCG2) did not alter 
subcellular distribution of GFP-ABCG2 either (Fig. 29).  
In summary, in the model cells used we found no impact of pharmacological 
PI3K/Akt/mTOR inhibitor treatment on plasma membrane localization of ABCG2. 
Pharmacological inhibition of EGFR upstream of the PI3K/Akt/mTOR signaling axis did 
not rapidly regulate cell surface levels of ABCG2 either. On the other hand, we provide 
biochemical evidence that ABCG2 is directly inhibited by LY294002 and rapamycin. 
Direct functional modulation of the transporter by these compounds should be taken into 
consideration when regulation of ABCG2 and a subsequent reversal of drug resistance by 
PI3K/Akt/mTOR signaling is investigated using these pharmacological signal 
transduction inhibitors. 
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6. DISCUSSION 
The ABCG2 efflux transporter is expressed in cancer cells and putative cancer stem 
cells (CSCs) and is responsible for conferring multiple drug resistance. Being expressed 
at pharmacological tissue barriers, such as the gut, the liver, the kidney, the blood-brain 
barrier or the blood-testis barrier, ABCG2 also has a major influence on the absorption, 
distribution, metabolism, excretion and toxicity (ADME-Tox) of orally administered 
drugs. The constitutive tyrosine kinase activity of Bcr-Abl or the Epidermal Growth 
Factor Receptor (EGFR) plays a causal role in the oncogenesis of chronic myeloid 
leukemia (CML) and various solid tumors, respectively. The Bcr-Abl and EGFR kinase 
enzymes are therefore intensively pursued as molecular drug targets. Currently, several 
small molecule inhibitors are available at the clinic for the specific targeting and 
elimination of kinase-addicted cancer cells. Clinically available inhibitors of Bcr-Abl 
include imatinib, and the second generation drugs nilotinib, dasatinib and bosutinib 
indicated in the treatment of CML (178,179) (Table 3). The EGFR inhibitor compounds 
gefitinib, vandetanib, pelitinib and neratinib are presently under clinical evaluation or use 
for treating a histologically diverse range of solid tumors, including lung cancer (183), 
breast cancer (187-189) and colorectal cancer (190) (Table 4). Similarly to conventional 
chemotherapeutics, resistance to targeted small molecule inhibitors represents a major 
impediment to successful cancer therapy. Together with genetic alterations of the target 
molecule or engagement of redundant signaling pathways, the ABCG2 multidrug 
transporter has also been implicated in the emergence of resistance against targeted 
drugs. Here, we provided detailed biochemical characterization regarding the interaction 
of ABCG2 with the aforementioned small molecule inhibitors of Bcr-Abl and EGFR. We 
analyzed whether ABCG2 modifies the intracellular action of these inhibitors; and 
whether the inhibitors are capable of inhibiting the function of the transporter. Given that 
ABCG2 is expressed on the targeted cancer cells or putative CSCs and also at 
pharmacological tissue barriers, interaction of these drugs with ABCG2 might 
significantly modify both the cellular anti-cancer efficiency at the target tumor site and 
the systemic biodistribution of the compounds in vivo. Importantly, as ABCG2 is 
currently considered to be a key contributor to drug resistance of CSCs, it is also 
reasonable to speculate that drugs which are not effluxed by ABCG2, or drugs which 
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inhibit the function of the transporter, may be efficient in chemo-sensitization and also in 
eradication of the drug resistant CSC compartment.  
In order to study the cellular effects of the small molecule inhibitors of Bcr-Abl, we 
generated and characterized a CML-derived Bcr-Abl+ K562 cellular model system, 
which stably expresses ABCG2 (Fig. 5-6). Using these model cells, we showed that 
ABCG2 prevented imatinib-induced cell death and erythroid differentiation in K562 cells 
(Fig. 7-8), confirming the findings of others (78,196,198) suggesting that imatinib is a 
substrate for the ABCG2 transporter. Similarly, ABCG2 conferred cellular resistance to 
the second generation Bcr-Abl inhibitors nilotinib and dasatinib that could be fully 
reversed by administration of the specific ABCG2 inhibitor FTC (Fig. 9). In contrast, the 
cellular toxicity of bosutinib was unaltered by the presence of ABCG2 (Fig. 9). Analysis 
of the phosphorylation of Bcr-Abl at Tyr177 in drug-treated K562 and K562/ABCG2 
cells revealed that in the presence of ABCG2 imatinib, nilotinib and dasatinib did not 
reach their intracellular target kinase and therefore could not inhibit its 
autophosphorylation (Fig. 10). In contrast, when K562/ABCG2 cells were simultaneously 
exposed to one of these Bcr-Abl inhibitors and FTC, decreased phosphorylation and an 
accompanying decrease in the levels of the Bcr-Abl kinase could be detected, similarly to 
those measured in parental K562 cells (Fig. 10-11). Levels of phosphorylated and total 
Bcr-Abl proteins were similar in K562 and K562/ABCG2 cells treated with bosutinib 
alone or in combination with FTC (Fig. 10-11). These results strongly suggested that 
ABCG2 restricts the intracellular efficiency of imatinib, nilotinib and dasatinib by active 
efflux, whereas rendered it unlikely that ABCG2 could reduce the intracellular 
concentration of bosutinib below the drug efficacy threshold in the applied concentration 
range. In lack of fluorescently or radioactively labeled Bcr-Abl inhibitors, we set out to 
develop a transport measurement protocol that relies on HPLC-MS based detection of the 
unlabeled drugs. Using this novel approach, we proved that ABCG2 efficiently 
transported nilotinib and dasatinib, while bosutinib proved not to be susceptible to 
ABCG2-mediated recognition and efflux (Fig. 12). Applying a similar experimental 
setup, in another study we could also demonstrate the ABCG2-mediated active transport 
of imatinib (223). 
ABCG2 and targeted anti-cancer drugs                                                 Csilla Hegedüs, PhD thesis 
 76
Notably, modulation of the ATPase activity of ABCG2 by the Bcr-Abl inhibitors 
measured in Sf9 insect cells could not precisely predict whether the drug was an ABCG2 
substrate. ABCG2 expressed in insect cells exhibits a relatively high ATPase activity in 
the absence of drugs, which had previously been believed to represent either an 
uncoupled state of the transporter or its ATPase stimulation by an unknown substrate 
resident in the insect membrane (41). An uncoupled ATPase activity was also suggested 
to be important for the promiscuous drug recognition capability of multidrug transporters 
(236). Studies performed on purified and reconstituted functional ABCG2 proposed that 
the basal ABCG2 ATPase is dependent on the lipid environment and especially on the 
presence of cholesterol but might not be coupled to any transport activity (237). It is 
widely accepted that drugs which can stimulate the relatively high ABCG2 ATPase in 
Sf9 insect membrane fragments are most probably transported substrates, as was seen in 
the case of nilotinib (Fig. 13). However, known ABCG2 substrates most probably 
transported at a lower rate have been described to decrease or not affect the basal ATPase 
activity of the transporter, as was also detected in our study in the case of imatinib and 
dasatinib, respectively (Fig. 4, 13). It is therefore important to highlight, that a 
combination of in vitro measurements are required to determine whether a drug interacts 
with ABCG2 and to further distinguish between substrates and inhibitors of the 
transporter. 
The cellular efficiency of gefitinib and the second generation inhibitors of EGFR were 
investigated in A431 epidermoid carcinoma cells which rely on mitogenic and survival 
signaling mediated by the overexpressed EGFR and therefore are sensitive to inhibition 
of the receptor. A431 cells stably expressing ABCG2 had been generated previously, and 
were applied to study the interaction of gefitinib and the transporter (203) (Fig. 16-17). 
Here, we showed that similarly to gefitinib, ABCG2 conferred resistance to pelitinib by 
limiting the access of the drugs (most probably by means of active efflux) to the 
intracellular kinase domain of EGFR and therefore preventing inhibition of EGFR 
autophosphorylation at Tyr1068 (Table 5, Fig. 19). Specific involvement of ABCG2 in 
the cellular resistance to gefitinib and pelitinib was verified by re-sensitization with FTC 
(Table 5). We also measured slightly increased resistance to neratinib in A431/ABCG2 
cells; however, it was not reversible with FTC (Table 5). It is possible, that 
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A431/ABCG2 cells acquired genetic alterations during the retroviral delivery of ABCG2, 
leading to the appearance of additional resistance mechanisms. Nevertheless the impact 
of ABCG2 could clearly be distinguished by administration of its specific inhibitor. 
Therefore, we concluded that susceptibility of A431 cells to vandetanib and neratinib was 
not influenced by the presence of ABCG2 (Table 5, Fig. 19). In case of the EGFR 
inhibitors, the ABCG2 ATPase data correlated with the results obtained in model cells, as 
we measured pronounced stimulation of the basal ABCG2 ATPase activity by gefitinib 
and pelitinib (Fig. 18A), which were also strongly suggested to be transported substrates 
of ABCG2 by the cellular toxicity (Table 5) and EGFR phosphorylation analyses (Fig. 
19A-B). 
In another series of experiments, we aimed to determine whether the small molecule 
kinase inhibitors could interfere with the function of ABCG2. In the case of nilotinib, 
dasatinib and bosutinib, we measured a concentration dependent inhibitory effect on the 
ABCG2-mediated transport of Hoechst 33342 (Fig. 14). Gefitinib, pelitinib, vandetanib 
and neratinib also inhibited ABCG2 function in a concentration-dependent manner. 
Besides inhibition of the quercetin-stimulated ABCG2 ATPase activity (Fig. 18B), we 
also detected increased 5D3 binding affinity of ABCG2 upon EGFR inhibitor treatment 
(Table 6), which corresponds to the inhibited conformation of the transporter (215,223). 
Accordingly, we showed that at relatively high concentrations, all four EGFR inhibitors 
were capable of inhibiting ABCG2-mediated transport of Hoechst 33342 (Table 6) and 
mitoxantrone (Fig. 20). Our cellular toxicity data strongly suggest that nilotinib, 
dasatinib, gefitinib and pelitinib are transported substrates of ABCG2 (Fig. 9A-B, Table 
5); therefore, blockade of ABCG2-mediated efflux by these compounds most probably 
occur via competitive inhibition. In the case of bosutinib, vandetanib and neratinib, 
additional direct transport or kinetic measurements involving various drug doses would 
be needed to determine whether these compounds are also competitive inhibitors of the 
transporter. The ATPase and 5D3 binding data strongly support that ABCG2 is directly 
inhibited by these drugs. In summary, all the herein investigated small molecule kinase 
inhibitors display potency to enhance accumulation and thereby restore cellular 
sensitivity toward ABCG2 substrate cytotoxic drugs by directly blocking ABCG2 
function. This finding highlights the possible clinical benefit of combining targeted Bcr-
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Abl or EGFR inhibitor-based therapies with conventional chemotherapeutic drugs that 
are substrates for ABCG2. 
Treatment-induced enhancement of functional ABCG2 expression could hamper the 
therapeutic efficacy of administered drugs. Therefore, we also investigated whether 
functional ABCG2 expression was altered in gefitinib-resistant NCI-H1650 G7 cells of 
non-small cell lung cancer (NSCLC) origin (Fig. 21). Gefitinib-resistant subclones of 
NCI-H1650 cells were reported to be devoid of secondary point mutations in EGFR and 
also lacked additional mutations in other oncogenes such as ErbB2, PTEN, KRAS or p53 
(214). Interestingly, we found enhanced ABCG2 protein expression in 3 out of 5 
gefitinib-resistant NCI-H1650 clones, and a corresponding resistance to an additional 
cytotoxic drug, mitoxantrone (Fig. 21). Although, only one case report described 
association of ABCG2 expression and acquired gefitinib-resistance in an NSCLC patient 
(125), our in vitro data point out, that in addition to acquired alterations in the target 
kinase or engagement of redundant signaling pathways, the involvement of ABCG2 in 
acquired EGFR inhibitor resistance and a corresponding emergence of a MDR phenotype 
could also be clinically relevant. Additionally, these cells might also serve as good 
models to investigate the molecular mechanism of gefitinib-mediated upregulation of 
ABCG2. Enhancement of ABCG2 protein expression by nuclear EGFR in gefitinib-
resistant A431 cells has recently been reported (238); therefore it is tempting to speculate 
that a similar mechanism is responsible for ABCG2 upregulation in NCI-H1650 G7 cells, 
which displayed increased internalization of ligand-activated EGFR (214). On the other 
hand, based on the chemoimmunity concept, gefitinib could also be recognized as a 
xenobiotic by the cellular detoxifying network, which might lead to ABCG2 upregulation 
independently from simultaneous alterations in EGFR signaling (46,194). 
Finally, we addressed the issue concerning the rapid regulation of the cell surface 
localization of ABCG2 by the PI3K/Akt signaling axis. Inhibition of Akt signaling was 
reported to result in rapid translocation of ABCG2 from the plasma membrane to 
intracellular compartments (79-84), which has also been associated with attenuated 
ABCG2 function (79,81,83,84) and subsequent reversal of drug resistance caused by the 
transporter (83,84). Nevertheless, opposing data regarding the involvement of the 
PI3K/Akt axis and the downstream mTOR kinase in the regulation of the plasma 
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membrane localization of ABCG2 has also been published (78,81). Here, using the 5D3 
antibody that recognizes an external epitope of ABCG2 or the fluorescently tagged GFP-
ABCG2 molecule, we demonstrated that pharmacological inhibition of the PI3K/Akt 
axis, or EGFR and mTOR upstream and downstream of PI3K/Akt, respectively, did not 
alter the cell surface localization and subcellular distribution of ABCG2 (Fig. 28-29). 
Interestingly, in the course of these studies we found that besides inhibiting their 
respective target kinases, the pharmacological PI3K inhibitor LY294002 and the 
downstream mTOR kinase inhibitor rapamycin also directly inhibit ABCG2 function 
(Table 7, Fig. 22, 25). In contrast, wortmannin, another commonly used pharmacological 
inhibitor of PI3K does not interact with the transporter. Therefore, we suggested that 
direct functional modulation of ABCG2 should also be taken into consideration when 
pharmacological inhibitors are applied to dissect the specific role of PI3K/Akt/mTOR 
signaling in the MDR phenomenon. A report, which appeared online exactly the same 
time as our paper was accepted, presented similar findings; and proposed that the 
versatile PI3K and ABCG2 inhibitory potential of LY294002 should be exploited to 
design novel therapeutic strategies for the targeting of drug resistant cancer cells or 
cancer stem cells which rely on Akt signaling for survival (239). 
In summary, we found that the herein investigated small molecule Bcr-Abl or EGFR 
inhibitors all interact with ABCG2. If local drug concentrations are low (due to poor 
bioavailability, or the size, stage, vascularization and poor penetration of the solid tumor), 
ABCG2 can confer imatinib, nilotinib, dasatinib, gefitinib or pelitinib resistance; 
however, anti-cancer efficiency of bosutinib, neratinib and vandetanib will most probably 
not be restricted by ABCG2. On the other hand, in ABCG2-expressing tissues where 
local drug concentrations are high (either at pharmacological tissue barriers or in tumor 
tissues where drug penetration is not limited), all of the investigated drugs can inhibit 
ABCG2 function and promote improved systemic distribution, intracellular accumulation 
and cytotoxic action of simultaneously administered ABCG2 substrate 
chemotherapeutics, thereby reversing multidrug resistance. These phenomena might 
significantly influence Bcr-Abl or EGFR inhibitor treatment outcomes in case of kinase-
addicted cancer cells or putative cancer stem cells with inherent or acquired ABCG2 
expression. 
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7. SUMMARY 
Human ABCG2 is a plasma membrane glycoprotein that provides physiological tissue 
protection against xenobiotics. ABCG2 influences the biodistribution of drugs through 
pharmacological tissue barriers, and confers multidrug resistance (MDR) to cancer cells. 
ABCG2 is the molecular determinant of the side population (SP) that is characteristically 
enriched in normal or cancer stem cells. Cancer cells often rely on unregulated kinase 
signaling, and small molecule kinase inhibitors are clinically applied to specifically target 
and eliminate kinase-addicted malignant cells. The constitutive tyrosine kinase activity of 
Bcr-Abl and Epidermal Growth Factor Receptor (EGFR) are required for the oncogenesis 
of chronic myeloid leukemia (CML) and various solid tumors, respectively. Here, we 
provided detailed biochemical characterization regarding the interaction of ABCG2 with 
clinically relevant small molecule inhibitors of Bcr-Abl and EGFR. We found that in Bcr-
Abl+ K562 cells, ABCG2 restricted the intracellular cytotoxic action of imatinib, 
nilotinib and dasatinib by limiting their intracellular access to their target kinase Bcr-Abl. 
In K562 cells, the cellular toxicity of bosutinib was unaltered by the presence of ABCG2. 
We proved that in contrast to bosutinib, ABCG2 actively transported nilotinib and 
dasatinib. In EGFR+ A431 cells, ABCG2 conferred cellular resistance to gefitinib and 
pelitinib, whereas it did not modify the intracellular action of vandetanib and neratinib. 
The molecular basis of resistance in A431/ABCG2 cells was the highly phosphorylated 
EGFR even in the presence of gefitinib and pelitinib. At higher doses, all of the 
investigated Bcr-Abl and EGFR inhibitors blocked ABCG2 function, thereby promoting 
accumulation of the ABCG2 substrates Hoechst 33342 and mitoxantrone. In addition, we 
demonstrated that gefitinib exposure enhanced the cell surface expression of ABCG2, 
whereas inhibition of the EGFR/PI3K/Akt/mTOR signaling axis did not result in rapid 
internalization of the transporter. In the course of these studies, we also found that 
LY294002 and rapamycin, inhibitors of the PI3-kinase and mTOR kinase respectively, 
directly inhibit the function of ABCG2. Our results should provide useful information 
about the therapeutic applicability of the clinically relevant drugs. Moreover, the finding 
that the investigated small molecule kinase inhibitors efficiently block ABCG2 function 
may help to design novel drug-combination therapeutic strategies. 
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8. ÖSSZEFOGLALÁS 
A humán ABCG2 egy plazmamembrán glikoprotein, amely fontos fiziológiás szerepet 
játszik a szervezet idegen anyagokkal szembeni védelmében. A farmakológiai 
barriereken kifejeződő ABCG2 befolyásolja a gyógyszerek szöveti eloszlását, 
túltermelődése pedig a rákos sejtek multidrog rezisztencia fenotípusának (MDR) 
kialakulásához vezet. Az ABCG2 funkciója alapján definiálható a normál és 
tumorszövetekből is elkülöníthető, jellemzően őssejtekben illetve tumor őssejtekben 
gazdag ún. side populáció (SP). Tumorsejtekben gyakran megfigyelhető bizonyos kináz 
enzimek szabályozatlan működése, ezért a klinikumban számos kis molekulasúlyú kináz 
inhibitor vegyületet alkalmaznak a kinázfüggő rosszindulatú sejtek célzott elpusztítására. 
A Bcr-Abl fehérje konstitutív tirozin kináz aktivitása a krónikus mieloid leukémia 
(CML), míg az Epidermális Növekedési Faktor Receptor (EGFR) szabályozatlan tirozin 
kináz aktivitása számos szolid tumor kialakításában játszik kulcsszerepet. Munkánkban 
biokémiai módszerek segítségével részletesen jellemeztük az ABCG2 kölcsönhatását a 
Bcr-Abl illetve az EGFR klinikumban alkalmazott kis molekulasúlyú gátlószereivel. Bcr-
Abl+ K562 sejtekben az ABCG2 csökkentette az imatinib, a nilotinib és a dasatinib sejten 
belüli toxikus hatását azáltal, hogy megakadályozta a Bcr-Abl célfehérjére kifejtett gátló 
hatásukat. Az ABCG2 nem befolyásolta a bosutinib K562 sejtekben kifejtett sejtpusztító 
hatását. Igazoltuk, hogy a bosutinibbel ellentétben a nilotinib és a dasatinib az ABCG2 
transzportált szubsztrátja. EGFR+ A431 sejtekben az ABCG2 gefitinib és pelitinib 
rezisztenciát okozott, míg a vandetanib és a neratinib toxikus hatásától nem védte meg a 
sejteket. A rezisztencia hátterében A431/ABCG2 sejtekben a gefitinib és pelitinib 
jelenlétében is kimutatható fokozott EGFR foszforiláció állt. Magasabb koncentrációkban 
az összes vizsgált vegyület gátolta az ABCG2 funkcióját, elősegítve az ABCG2 
szubsztrát Hoechst 33342 és mitoxantron akkumulációját. Bemutattuk, hogy gefitinib 
kezelés hatására megnő az ABCG2 kifejeződése a sejtfelszínen, ugyanakkor az 
EGFR/PI3K/Akt/mTOR jelpálya gátlása nem vezet a fehérje gyors internalizációjához. 
Munkánk során igazoltuk, hogy a PI3 kináz gátló LY294002 és az mTOR kináz gátló 
rapamycin gátolja az ABCG2 fehérje működését is. Eredményeink hasznosak lehetnek a 
vegyületek terápiás alkalmazhatóságának felmérésében, illetve az ABCG2 fehérje 
gátlásán keresztül hatékonyabbnak ígérkező kombinációs kezelések kidolgozásában. 
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